


# Recessive *PRDM13* mutations cause fatal perinatal brainstem dysfunction with cerebellar hypoplasia and disrupt Purkinje cell differentiation

## Graphical abstract



## Authors

Marion Coolen, Nami Altin, Karthyayani Rajamani, ..., Lydie Burglen, Sébastien Moutton, Vincent Cantagrel

## Correspondence

[vincent.cantagrel@inserm.fr](mailto:vincent.cantagrel@inserm.fr) (V.C.), [marion.coolen@inserm.fr](mailto:marion.coolen@inserm.fr) (M.C.)



# Recessive *PRDM13* mutations cause fatal perinatal brainstem dysfunction with cerebellar hypoplasia and disrupt Purkinje cell differentiation

Marion Coolen,<sup>1,\*</sup> Nami Altin,<sup>1</sup> Karthyayani Rajamani,<sup>1</sup> Eva Pereira,<sup>1</sup> Karine Siquier-Pernet,<sup>1</sup> Emilia Puig Lombardi,<sup>2</sup> Nadjeda Moreno,<sup>3</sup> Giulia Barcia,<sup>1,4</sup> Marianne Yvert,<sup>5</sup> Annie Laquerrière,<sup>6</sup> Aurore Pouliet,<sup>7</sup> Patrick Nitschké,<sup>2</sup> Nathalie Boddaert,<sup>8</sup> Antonio Rausell,<sup>9</sup> Féréchté Razavi,<sup>10</sup> Alexandra Afenjar,<sup>11</sup> Thierry Billette de Villemeur,<sup>12</sup> Almundher Al-Maawali,<sup>13,14</sup> Khalid Al-Thihli,<sup>13,14</sup> Julia Baptista,<sup>15,16</sup> Ana Belezza-Meireles,<sup>17</sup> Catherine Garel,<sup>18</sup> Marine Legendre,<sup>19</sup> Antoinette Gelot,<sup>20,21</sup> Lydie Burglen,<sup>1,11</sup> Sébastien Moutton,<sup>5</sup> and Vincent Cantagrel<sup>1,\*</sup>

## Summary

Pontocerebellar hypoplasias (PCHs) are congenital disorders characterized by hypoplasia or early atrophy of the cerebellum and brainstem, leading to a very limited motor and cognitive development. Although over 20 genes have been shown to be mutated in PCHs, a large proportion of affected individuals remains undiagnosed. We describe four families with children presenting with severe neonatal brainstem dysfunction and pronounced deficits in cognitive and motor development associated with four different bi-allelic mutations in *PRDM13*, including homozygous truncating variants in the most severely affected individuals. Brain MRI and fetopathological examination revealed a PCH-like phenotype, associated with major hypoplasia of inferior olive nuclei and dysplasia of the dentate nucleus. Notably, histopathological examinations highlighted a sparse and disorganized Purkinje cell layer in the cerebellum. *PRDM13* encodes a transcriptional repressor known to be critical for neuronal subtypes specification in the mouse retina and spinal cord but had not been implicated, so far, in hindbrain development. snRNA-seq data mining and *in situ* hybridization in humans show that *PRDM13* is expressed at early stages in the progenitors of the cerebellar ventricular zone, which gives rise to cerebellar GABAergic neurons, including Purkinje cells. We also show that loss of function of *prdm13* in zebrafish leads to a reduction in Purkinje cells numbers and a complete absence of the inferior olive nuclei. Altogether our data identified bi-allelic mutations in *PRDM13* as causing a olivopontocerebellar hypoplasia syndrome and suggest that early deregulations of the transcriptional control of neuronal fate specification could contribute to a significant number of cases.

## Introduction

Cerebellar hypoplasia (CH) refers to reduced cerebellar volume with a (near-) normal shape based, *in vivo*, on neuroimaging. It is a relatively common finding associated with a wide range of clinical features.<sup>1–3</sup> Additional neuroimaging findings, such as abnormal size or shape of the pons or the medulla oblongata, are key to categorize CH and better predict the clinical outcome. Early steps of

cerebellar development are shared with the brainstem explaining the frequent association of abnormal development of these structures in disorders such as Joubert syndrome (MIM: 213300), rhombencephalosynapsis,<sup>4</sup> pontine tegmental cap dysplasia (MIM: 614688), diencephalic–mesencephalic junction dysplasia (MIM: 251280), or pontocerebellar hypoplasia (PCH [MIM: 607596]).<sup>5</sup> PCH is described as a group of generally neurodegenerative disorders with prenatal onset,

<sup>1</sup>Université Paris Cité, Developmental Brain Disorders Laboratory, Imagine Institute, INSERM UMR 1163, Paris 75015, France; <sup>2</sup>Université Paris Cité, Bioinformatics Core Facility, Imagine Institute, INSERM UMR 1163, Paris 75015, France; <sup>3</sup>HDBR Developmental Biology and Cancer, UCL Great Ormond Street Institute of Child Health, University College London, London WC1N 1EH, UK; <sup>4</sup>Département de Génétique Médicale, AP-HP, Hôpital Necker-Enfants Malades, Paris 75015, France; <sup>5</sup>Centre Pluridisciplinaire de Diagnostic Prénatal, Pôle Mère Enfant, Maison de Santé Protestante Bordeaux Bagatelle, Talence 33400, France; <sup>6</sup>Normandie Univ, UNIROUEN, INSERM U1245; Rouen University Hospital, Department of Pathology, Normandy Centre for Genomic and Personalized Medicine, Rouen 76183, France; <sup>7</sup>Université Paris Cité, Genomics Platform, Imagine Institute, INSERM UMR 1163, Paris 75015, France; <sup>8</sup>Département de Radiologie Pédiatrique, INSERM UMR 1163 and INSERM U1299, Institut Imagine, AP-HP, Hôpital Necker-Enfants Malades, Paris 75015, France; <sup>9</sup>Université Paris Cité, INSERM UMR1163, Imagine Institute, Clinical Bioinformatics Laboratory and Molecular Genetics Service, Service de Médecine Génomique des Maladies Rares, AP-HP, Hôpital Necker-Enfants Malades, Paris 75015, France; <sup>10</sup>Unité d'Embryofœtopathologie, Service d'Histologie-Embryologie-Cytogénétique, Hôpital Necker-Enfants Malades, AP-HP, Paris 75015, France; <sup>11</sup>Centre de Référence des Malformations et Maladies Congénitales du Cervelet, Département de Génétique, AP-HP, Sorbonne Université, Hôpital Trousseau, Paris 75012, France; <sup>12</sup>Sorbonne Université, Service de Neuropédiatrie – Pathologie du Développement, Centre de Référence Déficiences Intellectuelles de Causes Rares et Polyhandicap, Hôpital Trousseau AP-HP, Paris 75012, France; <sup>13</sup>Department of Genetics, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat 123, Oman; <sup>14</sup>Genetic and Developmental Medicine Clinic, Sultan Qaboos University Hospital, Muscat 123, Oman; <sup>15</sup>Exeter Genomics Laboratory, Royal Devon & Exeter NHS Foundation Trust, Exeter EX2 5DW, UK; <sup>16</sup>Peninsula Medical School, Faculty of Health, University of Plymouth, Plymouth PL6 8BT, UK; <sup>17</sup>Clinical Genetics Department, University Hospitals Bristol and Weston, Bristol BS1 3NU, UK; <sup>18</sup>Service de Radiologie Pédiatrique, Hôpital Armand-Trousseau, Médecine Sorbonne Université, AP-HP, Paris 75012, France; <sup>19</sup>Service de Génétique Médicale, CHU Bordeaux, Pellegrin Hospital, Bordeaux 33300, France; <sup>20</sup>Neuropathology, Department of Pathology, Trousseau Hospital, AP-HP, Paris 75012, France; <sup>21</sup>INMED, Aix-Marseille University, INSERM UMR 1249, Marseille 13009, France

\*Correspondence: [vincent.cantagrel@inserm.fr](mailto:vincent.cantagrel@inserm.fr) (V.C.), [marion.coolen@inserm.fr](mailto:marion.coolen@inserm.fr) (M.C.)  
<https://doi.org/10.1016/j.ajhg.2022.03.010>

© 2022 American Society of Human Genetics.



progressive features, and at least 13 subtypes, based on neuropathological, clinical, and MRI criteria.<sup>6,7</sup> The prognosis of PCH disorders is poor and most affected individuals die during infancy or childhood. Despite the current effort to identify new genes associated with PCH, a large number of affected individuals remains without genetic diagnosis.<sup>6</sup> PCH often results from defects in apparently ubiquitous cellular processes such as tRNA synthesis, mitochondrial, glycosylation, inositol, or purine nucleotide metabolisms.<sup>5,7,8</sup> In parallel to the typical PCH presentation, mutations in *CASK* (MIM: 300172), *CHMP1A* (MIM: 164010), and *TBC1D23* (MIM: 617687) can lead to non-neurodegenerative disorders categorized respectively as PCH-like (or MICPCH [MIM: 300749]), PCH8,<sup>9</sup> and PCH11<sup>10</sup> disorders. Few cases with mutations in *PTF1A* (MIM: 607194) can be classified in this category of non-neurodegenerative syndrome, with an imaging pattern similar to PCH,<sup>11</sup> although these are characterized by an extremely severe impact on cerebellar development, associated with neonatal diabetes.<sup>12</sup> Interestingly, *PTF1A* is known to play a key role in hindbrain neural stem cell fate specification; whether other cell fate determinants contribute to congenital cerebellar disorders remains to be further explored. Indeed, for many key hindbrain stem cell fate determinants (e.g., *ATOH1* [MIM: 601461], *SKOR2* [MIM: 617138], *EN2* [MIM: 131310]), there are no associated and clearly defined Mendelian disorders yet. A better knowledge of the clinical consequences associated with the loss of function of these key genes would improve our understanding of their roles in human cerebellar and whole brain development.

*PRDM13* (MIM: 616741), a known target of *PTF1A*, encodes a transcriptional regulator previously implicated in neuronal specification in the retina and spinal cord.<sup>13–16</sup> However, until recently, no role had been attributed to this factor during cerebellar development. Indeed, Whittaker et al. reported a variant of this gene in three individuals with a hypogonadotropic hypogonadism syndrome associated with cerebellar hypoplasia.<sup>17</sup> Here, we report a significantly different syndrome on the basis of eight individuals from four families of different origins associated with loss-of-function mutations of *PRDM13*. This syndrome associates perinatal lethality with severe brainstem dysfunctions (e.g., feeding and respiratory difficulties, central apnea, bradycardia), together with persistent cerebellar hypoplasia. We also clearly establish that *PRDM13* is critically needed for the cerebellar GABAergic lineage differentiation, including Purkinje cells as well as for olivary nuclei genesis.

## Material and methods

### Patients' recruitment and investigation

Families 1 and 2 were recruited through the departments of genetics of the Pellegrin and the Necker Enfants Malades Hospitals and the French reference center for cerebellar

malformations and congenital diseases at Trousseau Hospital, France. Families 3 and 4 were identified through GeneMatcher.<sup>18</sup> Family 3 was referred to the clinical genetics department of university hospitals Bristol. Family 4 was recruited through the Genetic and Developmental Medicine Clinic Sultan Qaboos University Hospital, Oman. Written informed consents have been obtained both from all the participants and the legal representatives of all the children. Procedures followed were in accordance with the ethical standards of the national and institutional responsible committees.

Index cases of the four families have been analyzed via whole-exome sequencing (WES). For family 1, we performed trio WES (proband F.1-1 and both parents) with the Sure Select Human All Exon 58 Mb V6 protocol (Agilent Technologies) to prepare libraries that were sequenced with a HiSeq2500 system (Illumina) at the Imagine institute (Paris, France). Sequences were aligned to the reference human genome hg19 with the Burrows-Wheeler aligner (BWA). Downstream processing was carried out with the Genome Analysis Toolkit (GATK), SAMtools, and Picard. The annotation process was based on the latest release of the Ensembl database, gnomAD 2.1. Variants were annotated and analyzed with the Polyweb software interface designed by the Bioinformatics platform of Imagine-Université de Paris.<sup>19</sup> Family 2-1 proband was studied by WES performed in the proband only at Sorbonne Université, Trousseau Hospital, Paris, France, with the following details: SeqCap EZ MedExome capture kit (Roche) and sequence on Illumina NextSeq 500. The BaseSpace cloud computing platform with BWA, GATK Unified Genotyper, and the VariantStudio v.3.0 provided by Illumina was used for analysis. We performed targeted Sanger sequencing in the proband, parents, and affected sibling of family 2 to confirm the presence of the homozygous or heterozygous variants in affected children and parents, respectively. For family 3, WES was performed on both children and their healthy parents by the Exeter Genomics Laboratory (Exeter, UK). Libraries were prepared with the Twist Core Human Exome Kit (Twist Bioscience) and sequenced on the NextSeq 500 or NovaSeq seq platform (Illumina). Reads were aligned to human genome build hg19 and analyzed for sequence variants with a custom-developed analysis tool as previously described.<sup>20</sup> Family 4-3 proband was explored with clinical exome at BGI Europe (Copenhagen, Denmark). Exome capture was performed with the Agilent SureSelectXT Human All Exon 50 Mb Kit and sequencing was done on HiSeq2000TM (Illumina). Analysis was performed at Sultan Qaboos University Hospital (Muscat, Oman). An in-house database of 1,562 exomes was used for the filtering out of common population-specific variants.<sup>21</sup> Sanger sequencing was used for confirmation of the mutation in the affected individual. The DNA from parents and siblings was not available. Detailed clinical reports are included in [supplemental materials](#).

### *In situ* hybridization with human samples

Tissue collection, processing, and *in situ* hybridization (ISH) were performed at University College London/HDBR as previously described<sup>22</sup> and under the approval of the National Research Ethics Service (NRES). Briefly, tissues were fixed in 4% PFA/10% formalin overnight, embedded and sectioned at 6 microns. ISH was performed with RNAscope 2.5 HD Detection Kit and commercially available probes (Advanced Cell Diagnostics) for *PRDM13* and *PPIB* as a positive control with the references 459851 and 313901, respectively.

**Table 1. Source scRNA-seq and snRNA-seq datasets**

Dataset	Species	Source	Number of single cells
Cerebellum	mouse	GEO: GSE120372	9,353
Cerebellum – Purkinje neurons	human	Descartes Atlas	280,377
Cerebellum – inhibitory interneurons	human	Descartes Atlas	129,890
Cerebellum – granule neurons	human	Descartes Atlas	312,674
Cerebellum – astrocytes	human	Descartes Atlas	268,809
Cerebellum – vascular endothelial	human	Descartes Atlas	7,349
Cerebellum – unipolar brush	human	Descartes Atlas	52,646
Cerebellum – microglia	human	Descartes Atlas	4,428
Cerebellum – oligodendrocytes	human	Descartes Atlas	16,104
Cerebellum – SLC24A4_PEX5L positive cells	human	Descartes Atlas	19,722
Head – 24 hpf	zebrafish	GEO: GSE158142	9,105
Head – 36 hpf	zebrafish	GEO: GSE158142	10,719
Head – 48 hpf	zebrafish	GEO: GSE158142	15,558
Brain – 5 dpf	zebrafish	GEO: GSE158142	31,659
Brain – 8 dpf	zebrafish	GEO: GSE158142	28,689

### Single-cell RNA-sequencing data retrieval

Data re-analyzed as part of this study were retrieved from the Gene Expression Omnibus (GEO) public database under accessions GEO: GSE120372 for mouse embryonic cerebellum<sup>23</sup> and GEO: GSE158142 for zebrafish brain single-cell RNA sequencing (scRNA-seq) data<sup>24</sup> and from the Human Gene Expression During Development Atlas (Descartes, <https://descartes.brotmanbaty.org>) for human cerebellum single-nucleotide RNA-sequencing (snRNA-seq) data.<sup>25</sup> Mouse scRNA-seq data corresponds to a single developmental time point, embryonic day 13.5 (E13.5; n = 9,353 cells). Zebrafish scRNA-seq data were retrieved as processed R objects (.rds files) for different development stages (24 h post fertilization [hpf] to 8 days post fertilization [dpf]; n = 95,730 cells) and containing, among others, the assigned clusters information at different resolutions as shown in Raj et al.<sup>24</sup> Human cerebellum snRNA-seq data were retrieved as sparse gene counts by cell (n = 1,091,999 cells) along with cell-type assignments and gene annotations metadata (Table 1).

### Mouse and human cerebellum data processing

Data were imported into R v4.0.3 creating a Seurat v4.0 object<sup>26</sup> from counts. Further data processing followed the standard Seurat workflow for data normalization, dimensionality reduction (principal-component analysis, PCA), and graph-based clustering described in Butler et al.<sup>27</sup> Differentially expressed genes for the identified cell subpopulations were determined with Wilcoxon rank-sum tests on genes present in at least 20% of cells in the population of interest, only retaining positive gene markers. Testing was limited to genes that showed, on average, at least 0.2-fold difference (on a log-scale) between the different groups. Finally, genes displaying an adjusted p value inferior to 5% ( $p_{adj} < 0.05$ ) were retained.

### Visualization

*PRDM13*, *SOX2*, and *PTF1A* gene expression levels were represented over t-distributed stochastic neighbor embedding (t-SNE)

projection plots of distinct single cells at different developmental stages for zebrafish and mouse datasets or over uniform manifold approximation and projection (UMAP) plots for human cerebellum data. Simultaneous visualization of the expression levels of two different genes was performed with the *FeaturePlot* Seurat function (blend = TRUE parameter).

### Zebrafish lines and maintenance

Wild-type AB (ZFIN: ZDB-GENO-960809-7) and *prdm13*<sup>sa16464</sup> (ZFIN: ZDB-ALT-130411-4933) zebrafish were used for the experiments. The *prdm13*<sup>sa16464</sup> line was generated by the Zebrafish Mutation Project (ZMP)<sup>28</sup> and obtained from the EZRC center (Karlsruhe). Zebrafish were maintained with standard fish-keeping protocols, and experimental protocols conformed to French and European ethical and animal welfare directives (project authorization from the Ministère de l'Enseignement Supérieur, de la Recherche et de l'Innovation to M.C.). Genotyping of individuals from the *prdm13*<sup>sa16464</sup> line was performed by PCR with the following allele-specific primer pairs: 5'-GAGCGATACATTTGCCGG-3', 5'-CTCA GCAGGGGATATCTTCG-3' (WT allele); 5'-ATGGCCACAAACAA CACAAA-3', 5'-GGTATTTGAATATTCTCCAACAAGAT-3' (sa16464 allele).

Fresh fin clips from adult breeders or tails from fixed larvae were digested with Proteinase K (200 µg/mL) diluted in PCR buffer (10 mM Tris [pH 8], 2 mM EDTA, 0.2% Triton X-100) for 3 h at 55°C. Proteinase K was inactivated by a 5 min incubation at 95°C. PCR was performed with ReadyMix Taq PCR Reaction Mix (Sigma-Aldrich).

### Zebrafish embryos and tissue fixation

Zebrafish embryos and larvae were euthanized with tricaine (0.2% in embryo medium) and fixed overnight at 4°C in a 4% solution of paraformaldehyde (PFA) in PBS. For ISH on larval or juvenile brains (>5 dpf), brains were dissected out in cold PBS after fixation. Following fixation, samples were washed twice in PBS. Whole embryos and larvae were bleached with a peroxide-containing

bleaching solution (5% formamide, 0.5× saline sodium citrate [SSC], 3% H<sub>2</sub>O<sub>2</sub>) until dark pigments are no longer visible. Samples were either stored in PBS at 4°C (for immunohistochemistry [IHC]) or dehydrated in serial dilutions of methanol/PBS and stored in 100% methanol at –20°C (for ISH).

### RNA extraction

Dechorionated 24 hpf zebrafish embryos were euthanized on ice with tricaine (0.2% in embryo medium) and homogenized with a pestle in Trizol solution (ThermoFisher, 1 mL Trizol for 50–100 embryos). After a 5 min incubation at RT, chloroform was added (200 µL per mL of Trizol). The Eppendorf tube was shaken for 15 s and centrifuged at 12,000 g for 15 min. The upper phase was transferred to a fresh tube containing 500 µL Isopropanol and incubated at room temperature (RT) for 10 min. The tube was centrifuged at 12,000 g at 4°C for 10 min. After removal of supernatant, the pellet was washed with 70% EtOH and dissolved in 44 µL RNase-free water. Genomic DNA was removed with RNase-free DNase I treatment (NEB): 5 µL of 10× DNase buffer and 1 µL of RNase-free DNase was added to the 44 µL of RNA and the mix was incubated for 30 min at 37°C. To stop the reaction, we added 1 µL of 0.25 mM EDTA and incubated the tube at 65°C for 10 min. RNA concentration was measured with a nanodrop and stored at –80°C.

### Cloning

A fragment of zebrafish *prdm13* transcript (GenBank: NM\_001326454.1) covering the full-length coding sequence was amplified by PCR with the AccuPrime Taq DNA Polymerase System (Invitrogen) with the following primers: 5'-TGGATCCACA GAGCCAACCATGCAAACG-3' and 5'-TTCTAGATTAGTGTGTC GTAAAGTGG-3'.

The 1,881 nt-long PCR product was cloned inside the pCR2.1-TOPO plasmid with TOPO TA Cloning Kit (Invitrogen) according to the manufacturer's instructions. Clone sequences were verified by Sanger sequencing with universal M13 primers.

### RNA probes synthesis

For *prdm13* RNA probe synthesis, a DNA matrix was first generated by PCR from pCR2.1-*prdm13* plasmid with ReadyMix Taq PCR Reaction Mix (Sigma-Aldrich) and M13 primers. For *ptf1a* RNA probe synthesis, a plasmid containing the full-length *ptf1a* transcript (pBS-SK-*ptf1a*(FL)) was kindly donated by Masahiko Hibi (Nagoya University). 10 µg of plasmid DNA was linearized with EcoRI (NEB). DNA matrices were purified with PureLink PCR Micro Kit (Invitrogen) and eluted in 10 µL of RNase-free water. To generate DIG-labeled probes, we used 1 µg linearized plasmid as a template for transcription reaction with T3 or T7 RNA polymerase and DIG RNA Labeling Kit (Roche), according to the manufacturer's instructions. Transcription reaction was carried out for 3 h at 37°C, and a final incubation with DNase I was performed for removal of template DNA. Unincorporated nucleotides were removed with the ProbeQuant G-50 Micro Columns Kit (GE Healthcare). The RNA probe was stored at –80°C.

### Whole-mount ISH

ISH was carried out according to standard protocols.<sup>29</sup> Briefly, embryos or dissected brains were rehydrated, washed with PBST, and incubated in hybridization buffer at 65°C for 3 h. Brains were then incubated overnight at 65°C with DIG-labeled RNA probes diluted at 1/100 in hybridization buffer. We washed brains in serial

dilutions of hybridization buffer/2×SSC at 65°C to remove excess probe. An immunohistochemistry with anti-DIG antibody coupled to alkaline phosphatase (Roche, 1/5,000 dilution) was then performed. *In situ* signals were revealed either with NBT/BCIP (Roche) or Fast Red (Sigma) for fluorescent visualization. Following ISH, 2-month-old juvenile brains were sectioned with a vibratome (Leica VT1200) and mounted on microscope slides.

### Whole-mount IHC

For whole-mount IHC, zebrafish larvae were permeabilized in acetone at –20°C for 20 min. Samples were washed three times with PBST (0.1% Triton in PBS). Antigen retrieval was then performed through an incubation in HistoVT One (Nacalai Tesque) buffer for 1 h at 65°C. Larvae were washed three times for 5 min each with PBST and once in PBS-DT (0.1% Triton + 1% DMSO + 1% BSA in PBS). Samples were incubated in blocking buffer (5% goat serum in PBS-DT) for at least 1 h at RT and then with primary antibodies (see Table 2) diluted in blocking buffer for 24 h at 4°C. This was followed by six washes with PBST for 15 min. Larvae were incubated overnight at 4°C with secondary antibodies (see Table 2) diluted 1:1,000 in PBS-DT. The brains were then washed six times for 15 min in PBST. Brains were mounted in a glycerol solution (80% glycerol/PBS) for confocal imaging.

### Image acquisition

Brightfield images were acquired with a stereomicroscope (Leica M165FC) equipped with a color digital camera (Leica DFC450C). Fluorescent images were acquired on confocal microscopes (LSM700) with either a 20× air objective (Plan Apochromat 20×/0.8 M27) or a 40× oil objective (Plan-Apochromat 40×/1.3 Oil M27). 3D renderings were generated with the Imaris software (version 9.7.2, Bitplane). We cropped the 3D image to feature only the cerebellum as our region of interest and contrast was adjusted for each channel. For Sox2 immunostaining signals, background was subtracted with the remove outliers function of the ImageJ image analysis software (version 1.53c; <https://fiji.sc/>).

### Quantification and statistical analyses

3D Images were cropped and then segmented via semi-automatic detection with the Imaris spots function followed by manual curation. We segmented the whole cerebellum to quantify PARV+ Purkinje cells and CALB+ Eurydendroid cells. Data are presented as mean ± 95% confidence interval. Statistical analyses and graphical plots were done with GraphPad Prism version 9.2.0 for Windows (GraphPad Software, San Diego, California, USA, <https://www.graphpad.com/>). Deviation from Mendelian ratios was tested with Chi-square tests, and pairwise comparisons were carried out with two-tailed unpaired t tests.

## Results

### Identification of bi-allelic *PRDM13* pathogenic variants in families with brainstem dysfunction and cerebellar hypoplasia

In a collaborative effort to identify additional mechanisms underlying PCH and PCH-like disorders,<sup>5,19</sup> we recruited a French family of North-African origin with distant consanguinity (family 1) where three siblings presented with cerebellar vermis hypoplasia and brainstem dysgenesis (Figure 1A). For the proband (F.1-1) and sibling F.1-6, fetal


**Table 2. Antibodies**

Antibody name	Source	Identifier
Sheep Anti-Digoxigenin Fab fragments Antibody, AP Conjugated	Sigma-Aldrich	Cat# 11093274910; RRID: AB_514497
Mouse monoclonal (IgG1) Anti-SOX2 antibody [20G5]	Abcam	Cat# ab171380; RRID: AB_2732072
Mouse monoclonal (IgG2b) Anti-HuC/D, Clone 16A11	Thermo Fisher Scientific	Cat# A-21271; RRID:AB_221448
Rabbit Anti-Calbindin D-28k (for zebrafish)	Swant	Cat# CB-38a; RRID: AB_10000340
Mouse monoclonal Anti-Calbindin-D-28K, Clone CB-955 (for human)	Sigma-Aldrich	Cat# C9848, RRID: AB_476894
Mouse monoclonal (IgG2a) anti-PCNA Antibody, clone PC10	Santa Cruz Biotechnology	Cat# sc-56; RRID: AB_628110
Mouse polyclonal (IgG1) LHX1 antibody (4F2)	DSHB	Cat# 4F2 s; RRID: AB_531784
Mouse monoclonal (IgG1) anti-Parvalbumin	Millipore	Cat# MAB1572; RRID: AB_11211313
Goat anti-Mouse IgG1-488	Thermo Fisher Scientific	Cat# A-21121; RRID: AB_2535764
Goat anti-Mouse IgG2a-633	Thermo Fisher Scientific	Cat# A-21136, RRID: AB_2535775
Goat anti-Mouse IgG2b-633	Thermo Fisher Scientific	Cat# A-21146, RRID: AB_2535782
Goat anti-Rabbit-546	Thermo Fisher Scientific	Cat# A-11010, RRID: AB_2534077

brain MRI showed severe cerebellar hypoplasia with abnormal foliation (Figure 1B, Table 3, supplemental materials) and intact supratentorial structures. At birth, they presented with profound hypotonia and feeding difficulties with no sucking abilities. Several episodes of desaturation and altered consciousness related to a potential central origin required oxygenation therapy. The affected child F.1-1 died at the age of 25 months without reaching any developmental milestones and her sibling F.1-6 died at the age of 4 months. During the fourth pregnancy, similar manifestations as the first pregnancy were detected by close ultrasound follow-up and parents opted for a medical termination at 24 weeks of gestation (WG). Fetal pathological examination of F.1-4 further documented the disrupted development of the cerebellum and the brainstem (Figures 2A and 2B; see below), consistent with a type of PCH. Using whole-exome sequencing (WES), we identified a homozygous single base pair deletion in *PRDM13* in the three affected children. This variant, c.839del (p.Ala280Glyfs\*21), is predicted to cause a frameshift followed by premature termination after the first zinc finger domain (Figure 1D). *PRDM13* encodes a transcription factor with key functions in inhibitory neurons differentiation.<sup>13,14</sup> *Prdm13* knockout mice display dorsoventral cell specification defects in the fetal neural tube and die neonatally of unknown reasons.<sup>16</sup> Interestingly, a homozygous *Prdm13* deletion that removes the C-terminal part of the protein after the first zinc finger domain reflects a null phenotype.<sup>16</sup> On the basis of these first observations, we hypothesized that *PRDM13* loss of function could cause the neurodevelopmental disorder observed in family 1. In our effort to replicate this finding, we identified five other affected individuals from three additional families (Figure 1, Table 3) with highly comparable clinical phenotypes including cerebellar hypoplasia, brainstem dysfunction, and a diagnosis consistent with a form of PCH (individuals F.2-1, F.2-2, and F.4-3; Figures 1B and 1C). To have a broad view of the phenotypic consequences resulting from

*PRDM13* mutations, we used a genotype-first approach,<sup>18</sup> which led to the identification of families 3 and 4. We used WES systematically to uncover the genetic variants suspected to cause their disorder. For each family, the homozygous variant located in *PRDM13* is the only one compliant with autosomal recessive Mendelian inheritance and/or the most likely to disrupt gene function (Supplemental information). Affected individuals of families 2, 3, and 4 were homozygous for variants c.844del (p.Val282Serfs\*19), c.1856A>T (p.His619Leu), and c.800del (p.Gly267Aspfs\*34), respectively (GenBank: NM\_021620.3, NP\_067633.2; Table 3). All variants are either absent or encountered (at the heterozygous state) with a frequency lower than 0.001% in gnomAD (v2.1.1). The variant identified in family 3 is the only missense variant identified (p.His619Leu), affecting a fully conserved histidine (up to *S. cerevisiae*, not shown) with a CADD score of 32. This histidine residue (Figure 1D bottom-right, in red) is one of the invariant residues of the Cys2-His2 binding motif.<sup>30</sup> Consequently, the functionality of the third zinc finger domain is abrogated by the p.His619Leu variant.

Family 2 is also a French family of North-African origin with consanguinity. They had three pregnancy attempts; the second pregnancy resulted in a fetus who was interrupted for presenting with cerebellar and brainstem hypoplasia (fetus F.2-1, Figure 1B) and the third one resulted in a newborn who died at 22 days with a similar condition and profound hypotonia, inability to eat, and respiratory distress (infant F.2-2, Figure 1C). Family 3 is from the UK, from Pakistani origin, with two affected girls with a milder presentation. The F.3-1 elder sister presented with neonatal hypotonia, bradycardia, and respiratory distress. Brain MRI identified a non-progressive form of PCH. She had recurrent episodes with symptoms of dysautonomia associated with somnolence and then unresponsiveness. Similarly, F.3-2 presented with hypotonia and neonatal autonomic problems, including temperature instability and bradycardia. She



**Figure 1. Bi-allelic mutations in *PRDM13* in affected children and fetuses with posterior fossa anomalies**

(A) Families with predicted effect of *PRDM13* variants and pedigrees. All pathogenic variants are homozygous in affected individuals and segregated as recessive traits.

(B) T2-weighted fetal magnetic resonance images of control individual at 26 WG and affected individuals F.2-1, F.1-1, and F.1-6 at 26 WG, 30 WG, and 33 WG, respectively. Sagittal views are shown on top, and the bottom parts show coronal views for the control individual, F.2-1, and F.1-6 and axial views for F.1-1. The imaging shows reduced cerebellar vermis volume (yellow arrowhead) with abnormal or incomplete foliation and mild tapering of medulla oblongata for F.1-6.

(C) Sagittal T1-weighted (top, for control individual and F.4-3), Sagittal T2-weighted (top, for F.2-2), and coronal T2-weighted (bottom) brain magnetic resonance images of control individual and individuals F.4-3 and F.2-2. For both children, a small and dysmorphic vermis is visible on the sagittal slices and small hemispheres are detected on coronal views.

(D) Identified *PRDM13* mutations. Bottom-right, modeling of the third zinc finger domain based on ZFP568 structure (PDB: 5V3J). The mutated histidine residue (in red) is part of the Cys2-His2-binding motif. Blue, zinc ion.

<b>Table 3. Clinical table</b>								
	<b>Family 1</b>			<b>Family 2</b>		<b>Family 3</b>		<b>Family 4</b>
Individual identifier	E.1-1	F.1-4 (fetus)	F.1-6	E.2-1 (fetus)	F.2-2	E.3-1	F.3-2	E.4-3
Gender (M/F)	F	F	M	F	M	F	F	M
Age at last examination, age at death or fetal age	7 months, died at 25 months	24 GW	birth, died at 4 months	31 GW	2 days, died at 22 days	4 years 6 months	11 months	12 months, died at 16 months
<b>Genetic data</b>								
Ethnic origin	Tunisia			Algeria		Pakistan		Arab
Consanguinity (yes/no)	yes			yes		no (parents unsure)		yes
gDNA (GRCh38/hg38)	chr6(GRCh38): g.99613474del			chr6(GRCh38): g.99613479del		chr6(GRCh38): g.99614491A>T		chr6(GRCh38): g.99613435del
cDNA (GenBank: NM_021620.3)	c.839del			c.844del		c.1856A>T		c.800del
Protein	p.Ala280Glyfs*21			p.Val282Serfs*19		p.His619Leu		p.Gly267Aspfs*34
CADD-PHRED score	N/A			N/A		32		NA
<b>Prenatal findings</b>								
Prenatal growth retardation	–	–	–	–	–	+	+	–
Cerebellar vermis hypoplasia	+	+	+	+	+	not reported	not reported	not reported
<b>Growth</b>								
Delivery (weeks)	39	24	37	N/A	34	39	37	40
Neonatal symptoms	profound hypotonia	N/A	profound hypotonia	N/A	respiratory distress, axial hypotonia	temperature, HR and BP fluctuations; seizures	temperature, HR and BP fluctuations	respiratory distress, recurrent apnea
Likely autonomic symptoms	swallowing defect, desaturation, respiratory distress, bradypnea	N/A	swallowing defect, respiratory distress, no cough reflex, bradycardia	N/A	swallowing defect, respiratory distress, recurrent apnea, bradycardia	temperature, HR and BP fluctuations, respiratory distress	temperature, HR and BP fluctuations	respiratory distress, recurrent apnea
Weight at last examination (kg)	7 (–0.8 SD)	N/A	N/K	N/A	N/K	12.2 at 4 years 6 months (<–2 SD)	5.0 at 7.7 months (–3 SD)	5.2 (–4.5 SD)
HC at birth (cm)	N/A	N/A	N/K	N/A	33.5 (+1.3 SD)	N/K	N/K	34 (–1 SD)
HC at last examination (cm)	42 (–0.9 SD)	N/A	N/K	N/A	N/K	46.4 at 4 years 6 months (–2.7 SD)	38.3 at 33 weeks 5 days (–4.7 SD)	38 (–7 SD)
Presence of dysphagia	+, nasogastric tube feeding	N/A	+, nasogastric tube feeding	N/A	+, nasogastric tube feeding	–	–	+, nasogastric tube feeding

(Continued on next page)



**Table 3. Continued**

	Family 1		Family 2		Family 3		Family 4	
<b>Developmental history</b>								
Motor (normal/delayed/absent)	absent	N/A	absent	N/A	absent	delayed	delayed	absent
Global developmental delay (severity)	severe/profound	N/A	N/A	N/A	N/A	severe	mild	severe
<b>Neurological features</b>								
Axial hypotonia	+	N/A	+	N/A	+	+	+	+
Distal hypertonia	+	N/A	+	N/A	+	+	+	+
Spastic tetraplegia	+	N/A	N/K	N/A	N/K	–	–	+
Deep tendon reflexes	normal	N/A	N/K	N/A	N/K	reduced	normal	reduced
<b>Epilepsy</b>								
Seizure	–	N/A	–	N/A	–	neonatal period, focal seizures (on levetiracetam)	one seizure, on levetiracetam since	neonatal
<b>Brain MRI</b>								
Normal supratentorial brain	+	+	+	+	+	+	+	+
Cerebellar hemisphere hypoplasia	+	–	–	+	+	+	+	+
Cerebellar vermis hypoplasia	+	+	+	+	+	+	–	+
Brainstem hypoplasia	+	+	+	+	–	+	–	+
<b>Associated clinical features</b>								
Ophthalmological findings	abnormal ocular movement, suspicion of papillary edema or hypoplasia	N/A	bilateral retinal hemorrhages	N/A	no eye tracking	nystagmus with horizontal gaze, short sighted	–	–
Facial dysmorphism	microretrognathia	–	–	–	hypertelorism, epicanthic fold	–	–	hypertrichosis, low anterior hairline, upslanting palpebral fissures, epicanthic folds
Oral cavity findings	posterior cleft palate	posterior cleft palate	–	–	–	–	–	–

(Continued on next page)

	Family 1	Family 2	Family 3	Family 4
Cardiac abnormalities	–	trabecular ventricular septal defect	ostium secundum atrial septal defect, patent ductus arteriosus	–
Gastrointestinal abnormalities	–	–	gastroesophageal reflux	recurrent vomiting, gastroesophageal reflux
Respiratory system	oxygen therapy required (nasal cannula)	–	oxygen therapy, base of the tongue ptosis, no cough reflex	sinus rhythm with occasional marked sinus arrhythmia respiratory distress poor respiratory effort, ventilation dependence
Other	N/A	mild extremity malpositions	mild feet malpositions	episodic dystonia

Abbreviations: BP, blood pressure; EEG, electroencephalography; HC, head circumference; HR, heart rate; N/A, not applicable; N/K, not known; SD, standard deviation.

has an apparently less severe condition compared to her sister, without severe episodes of altered consciousness and autonomic instability, but she presented with developmental delay, slow weight gain, and cerebellar hemispheres hypoplasia with preserved brainstem on MRI.


Family 4 is a consanguineous family from Oman, with a single affected individual presenting with microcephaly, feeding difficulty, apnea, and hypoventilation and who died at 16 months. Brain MRI showed a dysplasia and a reduced size of the cerebellar vermis and the hemispheres (Figure 1C).

### Truncations of *PRDM13* are associated with early disruption of cerebellar and brainstem development

Neuropathological examination was performed for fetuses F.1-4 and F.2-1 and the infant F.2-2, covering the stages 24 GW, 31 GW, and 34 GW + 3 postnatal weeks (equivalent to 37 GW) (Figures 2A–2F). These three affected individuals displayed features distinctive of PCH<sup>31</sup> with unremarkable supra-tentorial structures: (1) reduced brainstem and cerebellum over total brain weight (3.4% for F.2-1 at 31 GW [–5.2 SD] and 3.7% for F.2-2 at 37 GW [–3.6 SD], Table S1), (2) transverse diameter of the cerebellum below the norm at 31 GW (<5th percentile) and 37 GW (<5th percentile), and (3) delayed/abnormal cerebellar foliation. At the histological level, the three individuals also presented comparable cerebellar and brainstem anomalies. Cerebellar vermis thus showed a hypoplastic but relatively preserved structure at 24 GW (Figures 2A, 2B, 2S, and 2T) and a severe hypoplasia with abnormal foliation at 31 GW and 37 GW (Figures 2C–2F, 2U, and 2V). The dentate nuclei were dysplastic and fragmented for the three affected individuals (Figures 2M–2R). At the level of the brainstem, olivary nuclei were fragmented or extremely hypoplastic (Figures 2G–2L) and pons nuclei appeared smaller (not shown). By contrast, pyramidal tracts were preserved. Histological examination of the cerebellar cortex, with a immunostaining against CALB to label Purkinje cells, revealed the presence of a disorganized Purkinje cell layer at 24 GW and 31 GW (Figures 2W–2Z) and a decreased density of these cells at 31 GW and 37 GW (Figures 2Y–2AB). Additionally, multiple Purkinje cells heterotopia are detected in the white-matter (Figure 2T, top-left inset) for all the affected fetuses and infant.

### *PRDM13* is expressed in neural stem cells of the hindbrain in mouse and human embryos

During mouse development, *Prdm13* was shown to be necessary to balance neuronal fates in the dorsal neural tube and in the retina<sup>13,15,16</sup> but no defined role of this factor was described during hindbrain development. Interestingly, the expression of *Prdm13* in the neural tube is under the control of *Ptf1a*.<sup>13</sup> *Ptf1a* is a bHLH (basic helix-loop-helix) proneural transcriptional factor and determines the fate of progenitors of the cerebellar ventricular zone (VZ),<sup>32–34</sup> which give rise to all cerebellar



**Figure 2. Neuropathological examination of the fetuses F.1-4 and F.2-1 and child F.2-2**

(A–F) Posterior view (B) and basal view (A and C–F) of the brain showing cerebellar hypoplasia in affected individuals compared to stage-matched control individuals. Scale bar: 10 mm. Cerebella are outlined with white dashed lines. (B) An incomplete covering of the 4<sup>th</sup> ventricle by the vermis is visible for the fetus F.1-4.

(G–L) Cross sections of the medulla stained with hematoxylin and eosin (HE) showing a fragmentation or extreme hypoplasia (arrows) of the olivary nuclei in affected individuals. Pyramidal tracts are clearly visible (\*) and inferior olivary nuclei are noted (arrowhead) in control individuals. Scale bar: 500  $\mu$ m.


(M–R) Horizontal (M) and sagittal (N–R) HE-stained sections showing a dysplasia and fragmentation of the dentate nucleus (arrows) in affected individuals. Arrowheads in control individuals point to the dentate nucleus. Scale bar: 500  $\mu$ m.

(S–V) Sagittal HE-stained sections at the level of the vermis showing delayed lobulation in the cerebellum of F.2-2 and hypoplasia severely affecting the anterior vermis (T and V). Primary fissures are indicated with arrowheads. Scale bar: 1 mm. Purkinje cell cluster heterotopia are visible in the white matter (T, top-left magnification).

(W–AB) Immunostaining of Purkinje cells with calbindin showing a decreased number and delayed maturation of Purkinje cells in the cerebellar cortex of affected individuals. Scale bar: 50  $\mu$ m

GABAergic neurons (Purkinje cells and inhibitory interneurons) and astrocytes. In addition, *Ptf1a* is necessary for the development of several brainstem nuclei, including the infe-

rior olivary nucleus (ION).<sup>35,36</sup> In order to better appreciate the expression of *PRDM13* during central nervous system development, we explored available transcriptomic datasets




**Figure 3. *PRDM13* expression in neural progenitors in the developing cerebellum and brainstem**

(A) Single-nucleus RNA-seq (snRNA-seq) data from human fetal cerebellum (9–21 PCW). snRNA-seq datasets were retrieved from the Human Gene Expression During Development Atlas<sup>25</sup> (Descartes, <https://descartes.brotmanbaty.org>) and analyzed with the Seurat package. Cells are visualized on uniform manifold approximation and projection (UMAP) plots. In the first panel, cells are color-coded according to cell annotations from the Descartes Atlas (PCs, Purkinje cells; UBCs, unipolar brush cells; GCs, granule cells; INs, interneurons; Astros, Astrocytes; OPCs, oligodendrocytes precursors; µglia, microglia; SPs, SLC24A4\_PEX5L\_positive cells; Endos, vascular endothelial cells). In the three other panels, cells are colored in graded intensities, reflecting the expression levels of *PRDM13*, *PTF1A*, and *SOX2*.

(B–D) Detection of *PRDM13* transcripts (red) by RNAscope *in situ* hybridization on coronal (B and C) or sagittal (D) sections through human embryos at Carnegie stage 13 (B) and 21 (C and D). (B') and (B''), (C') and (C''), (D') and (D'') are higher magnifications of the regions outlined by dotted squares in (B), (C), and (D), respectively. At CS13, specific expression of *PRDM13* is detected in the dorsal VZ of the caudal part of the hindbrain (Hb, B') and in the dorsal VZ of the caudal neural tube (NT, B''). At CS21, *PRDM13* starts to be expressed in the primordium of the cerebellum (Cb, C, C') while being maintained in the medulla oblongata (MO, C, D, D'') and spinal cord (SC, C, C'). In the cerebellum (D'), *PRDM13* is more specifically detected in the ventricular zone (VZ, black arrowheads), while it is absent from the rhombic lip (RL, white arrows). Scale bars: 100 µm (B) and 500 µm (C and D).

and performed ISH experiments. Analyzing a published scRNA-seq dataset from the mouse embryonic cerebellum at E13.5,<sup>23</sup> we observed that *Prdm13* is expressed in cell clusters corresponding to cerebellar progenitors of the VZ (Figure S1A) and co-expressing *Ptf1a* (Figures S1B and S1C). This confirmed a previous report showing expression of *Prdm13* in the mouse cerebellar VZ at E11.5.<sup>13</sup> To further demonstrate the link between *PRDM13* mutations and hindbrain developmental anomalies, we examined its expression during human brain development. We first exploited publicly available snRNA-seq datasets from fetal cerebellum samples (9–21 post-conception weeks [PCW])<sup>25</sup>

and observed an enriched expression of *PRDM13* in specific cell clusters (Figure 3A). These clusters are located at the crossroad between cell clusters annotated as fully differentiated cells that are Purkinje cells, inhibitory interneurons, and astrocytes. These clusters also show an enriched expression of both *PTF1A* and the neural stem cell marker *SOX2*, suggesting they might correspond to VZ progenitors (Figure 3A). To get a comprehensive picture of the spatio-temporal pattern of *PRDM13* expression during human brain development, we performed ISH on sections of human embryonic and fetal samples by using the highly-sensitive and specific RNAscope technology. Considering



**Figure 4. *prdm13* expression during zebrafish hindbrain development**

(A) Lateral view of a 3D reconstruction of the zebrafish hindbrain at 24 hpf showing the expression of *prdm13* (ISH, magenta) with a whole-mount immunostaining for the neuronal marker HuC (green). Cell nuclei are counterstained with DAPI (blue). A dotted line contours the hindbrain region. Cb, cerebellum; rh1–7, rhombomere 1–7; ov, otic vesicle. Scale bar: 50  $\mu$ m.

(B) Transverse section through the 3D reconstruction shown in (A) at the level of rhombomere 3 (left panel) and rhombomere 7 (right panel). Scale bar: 50  $\mu$ m.

(C) Optical z-plane showing *prdm13* expression (magenta) together with an immunostaining for Sox2 (blue) and HuC (green) in the cerebellum at 48 hpf. Cell nuclei are counterstained with DAPI (gray). At this stage, *prdm13* starts to be expressed in the cerebellar primordium, corresponding to the dorsal part of the first rhombomere, adjacent to the midbrain-hindbrain boundary (MHB). OT, optic tectum. Scale bar: 20  $\mu$ m.

(D) Schematic representation of the larval zebrafish brain at 6 days post fertilization (dpf), with a magnification on the larval cerebellum. Like in mammals, the zebrafish cerebellum develops from two distinct neurogenic progenitor pools: the rhombic lip (RL, green) and the ventricular zone (VZ, purple). The VZ gives rise to all the GABAergic neuronal populations, including Purkinje neurons, which migrate and align to form the Purkinje cell layer (PCL).

(E and F) Whole-mount ISH on zebrafish larval brains at 6 dpf showing the expression of *prdm13* (E) and *ptf1a* (F) in blue. Note the expression of *prdm13* and *ptf1a* in the cerebellar VZ (black arrowheads) and dorsal hindbrain (black arrows). Cb, cerebellum; OT, optic tectum; Tel, telencephalon; Hyp, hypothalamus; MO: medulla oblongata. Scale bar: 100  $\mu$ m.

(G) Lateral view of a 3D reconstruction of the zebrafish cerebellum at 6 dpf showing the expression of *prdm13* (ISH, magenta) with a whole-mount immunostaining for the proliferation marker PCNA (green). Cell nuclei are counterstained with DAPI (blue). Dotted lines outline the cerebellar primordium. *prdm13* transcripts are detected in proliferating progenitors of the VZ (white arrowheads). Scale bar: 10  $\mu$ m.

(legend continued on next page)

the early expression of *PRDM13* seen in the embryonic mouse cerebellum, we studied *PRDM13* expression over an extended temporal window from Carnegie stage 13 (CS13, corresponding to ~32 days post conception [dpc]) to 15 PCW. At CS13, we detected specific expression of *PRDM13* in the dorsal neural tube, similarly to the described expression pattern in mice (Figures 3B and 3B'). We also detected *PRDM13* transcripts in dorsal ventricular domains of the hindbrain (Figures 3B and 3B'). These expression domains are maintained at CS21 (~51 dpc) (Figures 3C, 3C', 3D, and 3D'). At this stage, additional expression sites become apparent, and notably, a strong expression is detected in the cerebellum at the level of the ventricular zone (Figures 3C, 3C', 3D, and 3D'). This cerebellar expression of *PRDM13* is quite transient, as it faints already at 10 PCW (Figure S1D); at this stage *PRDM13* expression is maintained only in scattered cells of the subventricular zone (Figure S1D'). Expression of *PRDM13* was no longer detected in the cerebellum at 15 PCW (Figure S1E). We also detected expression of *PRDM13* in the inner layer of the developing retina (Figures S1F and S1F'), consistent with the described role of *Prdm13* in the development of amacrine cells in mice.<sup>15</sup> Altogether, our data show that *PRDM13* is expressed in human progenitors of the cerebellum and hindbrain at an early neurogenic phase. This result further argues for the implication of this gene in olivopontocerebellar hypoplasia and points to a pathological mechanism involving neuronal fate misspecification. Consistent with the absence of obvious supratentorial anomalies in the individuals investigated in this study, no expression of *PRDM13* was detected in the forebrain and the midbrain, except for the hypothalamus (Figures S1G and S1G').


### Homozygous disruption of *prdm13* causes hindbrain developmental defects in zebrafish

To validate the implication of *PRDM13* in hindbrain development, we took advantage of the zebrafish. Its cerebellar development relies on homologous transcription factors<sup>37</sup> and its genome includes a unique ortholog of *PRDM13*. To further validate this model, we first analyzed the expression of *prdm13* during zebrafish brain development by using ISH. At 24 hpf, we detected specific *prdm13* expression in rhombomeres 2–7, with a higher intensity in the ventricular zone and in HuC-positive differentiating neurons of rhombomere 7 (r7) (Figures 4A and 4B, right panel). This expression in the developing hindbrain, particularly enriched in r7, was also confirmed by the analysis of available scRNA-seq data from 24 hpf

zebrafish embryos<sup>24</sup> (Figures S2A and S2B). Of note, dorsal progenitors from r7, expressing *ptf1a*, were recently shown to give rise to neurons of inferior olivary nuclei.<sup>35,38</sup> Additionally, scRNA-seq data revealed expression of zebrafish *prdm13* in pharyngeal arch cells at this stage (Figures S2A and S2B). At 48 hpf, we could detect expression of *prdm13* in the cerebellar primordium located in the dorsal part of r1 (Figure 4C). The expression of *prdm13* in the cerebellar VZ is maintained at larval stages (Figure 4E) and is very similar to the expression of *ptf1a* (Figure 4F). *prdm13* transcripts are located in VZ neural progenitors expressing Sox2 and PCNA and also at least transiently in differentiating cells exiting the VZ (Figures 4C and 4G). Analysis of scRNA-seq data from 5 dpf larval brain also highlighted the expression of *prdm13* in cell clusters annotated as “neural progenitors” and co-expressing *ptf1a* and *sox2* (Figures 4H and S2E). The expression of *prdm13* in the cerebellar and hindbrain progenitors is maintained in the 2-month-old juvenile zebrafish brain (Figures S2F and S2F'), which is probably related to the maintained neurogenic activity of these regions beyond developmental stages in zebrafish. As in human embryos, we also observed additional expression sites for *prdm13* in the developing eye and hypothalamus (Figures 4H and S2E). Altogether, our results demonstrate that *prdm13* expression pattern is highly conserved across vertebrates and is consistent with an early role in hindbrain neurogenesis. It also validated the zebrafish as an appropriate model for functional studies of *PRDM13*-related neurodevelopmental anomalies.

We thus analyzed the phenotype of a zebrafish homozygous mutant for *prdm13*, available from the Zebrafish Mutation Project (*sa16464*).<sup>28</sup> The mutant allele is a point mutation that creates a premature stop codon and leads to a truncation of the Zn fingers domains, comparable to the mutations identified in families 1, 2, and 4 (Figure 5A). Homozygous mutant embryos *prdm13*<sup>2<sup>sa16464</sup>/sa16464</sup> (hereafter referred to as *prdm13*<sup>-/-</sup>), obtained from a cross between heterozygous *prdm13*<sup>sa16464/+</sup> fish (*prdm13*<sup>+/-</sup>), survive at least until 7 dpf, when larval lethality begins to be observed. Genotyping individual larvae demonstrated a distortion of the Mendelian distribution at 9 dpf (Chi-square test;  $p = 0.0002$ ) due to the death of *prdm13*<sup>-/-</sup> mutant larvae (Figure 5B). Although *prdm13*<sup>-/-</sup> larvae have a roughly normal morphology, we noted that they present an abnormal body curvature and lower jaw morphology (Figure 5C). We then explored their brain phenotype, more particularly the cerebellum and posterior hindbrain. We fluorescently labeled cerebellar Purkinje

(H) t-distributed stochastic neighbor embedding (t-SNE) projection plots of distinct single-cell populations obtained from the zebrafish brain at 5 dpf. The zebrafish single-cell RNA-seq (scRNA-seq) dataset was retrieved from the Gene Expression Omnibus (GEO) public database under accession GEO: GSE158142.<sup>24</sup> In the first panel, cells are color-coded according to cluster annotations from the original publication.<sup>24</sup> In the three other panels, cells are colored in graded intensities, reflecting the expression levels of *prdm13*, *ptf1a*, and *sox2*. Clusters in which *prdm13* expression is enriched are circled with dotted lines. *prdm13* expression is enriched in clusters 13, 25, 30, and 38, corresponding to neural progenitors (NPCs) that are also enriched for *ptf1a* and *sox2*. Expression of *prdm13* is also detected in clusters 1, 34, and 35, which are annotated as hypothalamic clusters (Hyp); 21, which corresponds to amacrine cells (ACs); and 45, which correspond to Müller glia (MG).



**Figure 5. Homozygous *prdm13* disruption causes reduction in Purkinje neurons numbers and loss of inferior olive neurons in zebrafish**

(A) Zebrafish mutant allele *sa16484*. The mutant allele is a nonsense single-nucleotide mutation, leading to a truncation of the protein at the level of the first Zn finger domain. (B) Proportion of embryos of each genotype inside the progeny of a cross between two heterozygous fish from the *prdm13* *sa16484* line at different stages. The number of embryos genotyped per stage is indicated underneath each bar. At 9 dpf, the proportions differ significantly from the expected ratios (Chi-square test;  $p = 0.0002$ ).

(C) Photographs of wild-type and homozygous mutant larvae from the *prdm13* *sa16484* line at 7 dpf. (C') and (C'') are higher magnification of the head regions of a wild-type (C') and homozygous mutant (C'') larva. Homozygous *prdm13* mutant larvae display an abnormal body curvature and lower jaw morphology (arrow in C''). Scale bar: 500  $\mu\text{m}$ . (D) 3D reconstructions of the hindbrain in dorsal view from a wild-type (top panels) and a homozygous mutant (bottom panels) larva at 6 dpf. Larval brains were immunostained for parvalbumin (PARV, green), a marker of Purkinje cells (PCs), and calbindin (CALB, magenta), a marker of some eurydendroid cells (ECs). The panels on the right show a higher magnification of the cerebellum; the last ones show the distribution of PCs (green) and ECs (magenta), as determined by 3D-image segmentation of the cerebellar region. Scale bar: 50  $\mu\text{m}$ .

(E and F) Total number of PARV+ PCs (E) and CALB+ ECs (F) in wild-type and mutant *prdm13* larvae. Data are presented as mean  $\pm$  95% confidence interval. The number of PCs is significantly reduced in mutant larvae ( $n = 5$  [*prdm13*<sup>+/+</sup>] and  $n = 6$  [*prdm13*<sup>-/-</sup>]; unpaired t test  $p = 0.011$ ), while no significant changes in EC numbers are observed ( $n = 3$  [*prdm13*<sup>-/-</sup>] and  $n = 3$  [*prdm13*<sup>+/+</sup>]; unpaired t test  $p = 0.7854$ ).

(G) Representative images of 3D reconstructions of the hindbrain from a wild-type (top panels) and a homozygous mutant (bottom panels) larva at 7 dpf. Larval brains were immunostained for LHX1 (green), which labels inferior olivary nucleus projection neurons (white arrow). The left and middle panels are lateral views and the right panels are ventral views centered on the inferior olivary nuclei (IONs). Note the absence of ION neurons in mutant larvae (four larvae were immunostained for each genotype). Scale bar: 20  $\mu\text{m}$ .

(H) Schematic representation of the phenotype of *prdm13* mutant larvae, which present a reduction in the number of Purkinje cells (red) and an absence of ION projection neurons (green), which normally send climbing fibers onto PCs.

*prdm13*<sup>-/-</sup> larvae when compared to wild-type *prdm13*<sup>+/+</sup> larvae (Figure 5E;  $n = 5$  [*prdm13*<sup>-/-</sup>] and  $n = 6$  [*prdm13*<sup>+/+</sup>]; unpaired t test  $p = 0.011$ ). In contrast, other cell populations such as CALB+ Eurydendroid cells (ECs), functionally equivalent of deep cerebellar nuclei in mammals,<sup>37</sup> were not affected (Figure 5F;  $n = 3$  [*prdm13*<sup>-/-</sup>] and  $n = 3$  [*prdm13*<sup>+/+</sup>]; unpaired t test  $p = 0.7854$ ). We also labeled ION neurons with an antibody against LHX1 in wild-type and mutant larvae (Figure 5G) and observed a total absence of these neurons in *prdm13*<sup>-/-</sup> larvae. Altogether, these data indicate that homozygous disruption of *prdm13* in zebrafish leads to a late lethality in larvae, associated with a

cells with an antibody against Pvalb7, a validated marker in this species,<sup>39</sup> and quantified these cells in 3D reconstructions (Figure 5D). We could show that the number of Purkinje cells was significantly reduced in

specific reduction in Purkinje cell numbers and an absence of ION neurons (Figure 5H). This phenotype shares striking similarities with the clinical features and neuropathological findings in the affected child and fetuses with bi-allelic *PRDM13* mutations, further corroborating their causative role in the pathology.

## Discussion

Several PRDM transcription factors are already known to be involved in central nervous system development and diseases. *PRDM8* (MIM: 616639) regulates cadherin-11 to ensure proper neural circuit formation<sup>40</sup> and is mutated in progressive myoclonic epilepsy-10 (EPM10 [MIM: 616640]). *PRDM12* [MIM: 616458] plays a role in sensory neuron perception and is mutated in hereditary sensory and autonomic neuropathy type VIII (HSAN8 [MIM: 616488]). *PRDM15* [MIM: 617692] is mutated in syndromes with neurodevelopmental defects and a progressive nephropathy.<sup>41</sup> All these genes play a critical role in the development as illustrated by the embryonic lethality or severe neurodevelopmental phenotypes of their respective knockout mouse mutants. Likewise, the knockout of *Prdm13* in mouse, as well as a deletion of its three last Zn finger domains, cause neonatal death, although the cause of this death has not been investigated.<sup>16</sup> However, until recently, the only congenital disorders implicating *PRDM13* were macular dystrophies. Tandem duplications and single-nucleotide variants in the non-coding region of *PRDM13* have thus been reported to cause North Carolina macular dystrophies (NCMD [MIM: 136550]) and other similar autosomal dominant retinal dystrophies.<sup>42,43</sup> The implication of *PRDM13* in these pathologies is most likely linked to the highly specific expression of *PRDM13* in the inner layer of the embryonic human retina that we report in this study and with the role of *Prdm13* in the specification of a subset of amacrine cells demonstrated in mice.<sup>15</sup> The precise molecular mechanism underlying these *PRDM13*-associated retinopathies is unknown but is suspected to result from an upregulation of *PRDM13*.<sup>44</sup> This is compatible with our current findings, as we demonstrate that loss-of-function variants cause a very different clinical phenotype. Visual acuity could not be assessed in most of the affected individuals with truncating variants, as they died early during infancy and eye histological examination was not performed. The eldest sister from family 3, carrying a missense mutation and presenting with milder clinical features had a normal fundus exam, although she presented with high myopia. As we show that *PRDM13* is expressed in multiple brain regions that are not affected in NCMD, it is also possible that NCMD-causing variants lead to eye-specific deregulations of *PRDM13* expression.

During the preparation of this manuscript, Whittaker et al.<sup>17</sup> reported a recessive *PRDM13* mutation associated with hypogonadotropic hypogonadism syndrome. The

three affected individuals are adult or adolescent presenting with scoliosis, sexual development defects, and moderate intellectual deficit. Two of them also present with cerebellar hypoplasia. The authors of this study hypothesized that the mutation identified, a deletion encompassing a splice acceptor site, leads to a truncation of the four Zn finger domains and cause the phenotype. This would be at odds with the lethal phenotype observed in the mouse mutant with a deletion of the Zn finger domains.<sup>16</sup> Then, using a different *Prdm13* mouse mutant, deleted for the PR domain, Whittaker et al. demonstrated a role for *Prdm13* in cerebellar development but without finding any locomotor or Purkinje cell differentiation defect.

Here, we present multiple important differences with the study of Whittaker et al. First, we report a significantly different syndrome based on eight individuals from four families of different origins. This syndrome associates perinatal lethality with brainstem dysfunctions (e.g., respiratory and swallowing defects) and/or severe brainstem malformation, together with persistent cerebellar hypoplasia. Consistently with the previously published mouse data, and further demonstrating the critical requirement of the Zn finger domains, three out of the four families carry mutations of *PRDM13* that truncate these domains and the last is predicted to disrupt one of them. Using a zebrafish mutant lacking the four Zn finger domains, we further validated the critical need for *PRDM13* during brainstem development in vertebrates. Second, we demonstrate that *PRDM13* shows a strong and spatio-temporally restricted expression pattern during early human hindbrain development, explaining why Whittaker et al. can barely detect *PRDM13* expression in CS23-stage human fetus. Third, correlations of human and zebrafish data from samples with truncation of *PRDM13* demonstrate the requirement of this gene for Purkinje cell differentiation. It can be speculated that the clinical differences observed between the two studies come from the specific mutation identified by Whittaker et al. that might alter splicing but still allows for the production of some functional transcripts. However, the exact consequence of this splicing mutation on *PRDM13* transcripts remains to be assessed. The partial overlap with our clinical findings, with the presence of cerebellar hypoplasia and global developmental delay, suggests that this variant might be a hypomorphic allele. We note that affected individuals carrying missense variants (i.e., family 3) also present with milder clinical phenotypes in our study. The presence of the three other functional Zn fingers might be sufficient to maintain the functionality of the protein to a certain degree. However, unlike the affected individuals from the aforementioned study, they do not present scoliosis, although postural kyphosis has been detected in the child F.3-1. Clinical follow-up of the very young affected children from family 3 will help to determine whether impaired sexual development, hypogonadism, and progressive scoliosis are consistent clinical



features associated with partial loss of function of *PRDM13*.

Among the clinical features in affected individuals with *PRDM13* mutation, some variable features are observed (e.g., cardiac malformation in family 1, see Table 3) and could involve recessive variants other than *PRDM13* mutations.<sup>45</sup> Differently, epilepsy or seizures have been observed in several members of families 3 and 4. Epilepsy is also present in typical PCH cases that are generally associated with mutations in ubiquitously expressed genes (e.g., genes involved in tRNA processing).<sup>7</sup> Here, *PRDM13* has a very restricted expression pattern and a direct impact of its mutations in tissues where it is not detected, such as the cerebral cortex, is unlikely. However, a protective role of the cerebellum, through the inhibition of aberrant discharges that lead to cortical seizures, has been suggested<sup>46</sup> and so an indirect contribution of the cerebellar malformation to this epilepsy phenotype could be speculated.

Using a meta-analysis of scRNA-seq data as well as a detailed expression study performed during zebrafish hindbrain development, we could define original molecular hypotheses to understand *PRDM13*'s role in brainstem and cerebellar Purkinje cells development. Several lines of evidence support the idea that these defects result from cell-autonomous neuronal misspecification. Indeed, we show that *prdm13* is expressed, together with *ptf1a*, in progenitors of the cerebellar VZ and dorsal ventricular zone of rhombomere 7. These *Ptf1a*<sup>+</sup> progenitor domains have been demonstrated to generate, respectively, Purkinje cells and ION neurons.<sup>32,35,36,38,47</sup> Besides, *Ptf1a* is required cell autonomously for proper identity specification in neuronal precursors in the retina, spinal cord, cerebellum, and posterior hindbrain.<sup>32,35,36,48,49</sup> In the dorsal spinal cord, *Ptf1a* loss of function thus induces a loss of GABAergic neurons.<sup>49</sup> Part of *Ptf1a* function is mediated by the transcriptional activation of its direct target *Prdm13*, which in turn inhibits the expression of determinants of the alternative glutamatergic fate, such as *Tlx1/3* and *Lmx1b*.<sup>13,16</sup> Accordingly, the *Prdm13* loss-of-function phenotype in the spinal cord resembles the one observed in *Ptf1a* null mutants, albeit less severe, as it affects mostly early-born neurons.<sup>16</sup> In the zebrafish cerebellum, we show that the phenotype of *prdm13* loss-of-function mutant is comparable but milder to *ptf1a* mutant.<sup>38</sup> This is also the case in humans, as *PTF1A* loss of function leads to a much more severe cerebellar hypoplasia than the one we observed in presence of *PRDM13* mutations. Altogether, these data are in line with the hypothesis that, in the developing cerebellum and ION, *PRDM13* plays a cell-autonomous role in neural progenitors fate specification, downstream of *PTF1A*.

Our findings also suggest that *PRDM13* loss of function could impact cerebellar development both directly and indirectly by impairing the development of key afferent pathways of the cerebellum. Indeed, inferior olivary nuclei are the origins of major cerebellar inputs that influence

Purkinje cells maturation.<sup>50</sup> Interestingly, lesions, size or functional abnormalities of key nuclei of the olivo-cerebellar complex have been observed in sudden infant death syndrome (SIDS).<sup>51–53</sup> Therefore, a defect in these structures could be directly involved in the respiratory symptoms observed in SIDS and in individuals with *PRDM13* mutations. Alternatively, other brainstem nuclei could also be affected. Indeed, in mice, *Ptf1a* loss of function also affects the neuronal composition of brainstem nuclei involved in somatosensory and viscerosensory control circuits.<sup>36</sup> Among these nuclei, *Ptf1a* is required for the proper development of the nucleus of the solitary tract that is a major sensory nucleus of the dorsal medulla oblongata receiving cardiorespiratory afferent inputs among others. Considering the likely involvement of *Prdm13* in these developmental processes, its disruption may also impair the development of these nervous centers and thereby explain the various brainstem dysfunctions shared by affected individuals with bi-allelic *PRDM13* mutations.

Like the cerebral cortex, the cerebellum is a brain region that has undergone during evolution a strong expansion and complexification in the human lineage. Recent studies in human early embryos showed that cerebellar germinal zones present some human-specific features.<sup>54</sup> Notably, as in the cerebral cortex, an expanded subventricular proliferation zone (SVZ) is detected above the VZ in the developing human cerebellum. However, little is known about the diversity of human VZ/SVZ progenitors and the molecular mechanisms involved in this expansion. Our study highlights how defects in the transcriptional regulation of these early human-tailored neurogenic steps can contribute to severe neurodevelopmental disorders of the brainstem and cerebellum. Exploring further this early transcriptional network in a human context<sup>55</sup> will be of high interest to understand these pathologies.

#### Data and code availability

This study did not generate datasets or code.

#### Supplemental information

Supplemental information can be found online at <https://doi.org/10.1016/j.ajhg.2022.03.010>.

#### Acknowledgments

The project is funded by the Agence Nationale de la Recherche ANR-16-CE12-0005-01, the Fondation pour la Recherche Médicale FRM-DEQ20160334938, and the patient association CSC “Connaitre les syndromes Cérébelleux.” This work was also supported by state funding from the Agence Nationale de la Recherche under “Investissements d’avenir” program (ANR-10-IAHU-01), the Fondation Bettencourt Schueller, and the MSD Avenir Fund (DEVO-DECODE project). The human embryonic and fetal material was provided by the Joint MRC-Wellcome (MR/R006237/1) Human Developmental Biology Resource

(<https://www.hdbbr.org>). We would like to thank S. Amat, F. Pelluard, and I. Deryabin for providing clinical information and material; M. Hibi (Nagoya University) for providing the zebrafish *ptf1a* probe; B. Crespo for technical help; and L. Colleaux for guidance during the course of the project.

## Declaration of interests

The authors declare no competing interests.

Received: November 16, 2021

Accepted: March 11, 2022

Published: April 6, 2022

## Web resources

CADD, <https://cadd.gs.washington.edu/snv>

dbSNP database, <https://www.ncbi.nlm.nih.gov/snp/?cmd=search>

Ensembl genome assembly GRCh37, [http://grch37.ensembl.org/Homo\\_sapiens/Info/Index](http://grch37.ensembl.org/Homo_sapiens/Info/Index)

ESP database, <https://evs.gs.washington.edu/EVS/>

Gene Expression Omnibus database, <https://www.ncbi.nlm.nih.gov/geo/>

gnomAD, <https://gnomad.broadinstitute.org>

Human single-cell RNA-seq dataset, Descartes, <https://descartes.brotmanbaty.org>

Online Mendelian Inheritance in Man, <https://www.omim.org>

## References

1. Accogli, A., Addour-Boudrahem, N., and Srouf, M. (2021). Diagnostic Approach to Cerebellar Hypoplasia. *Cerebellum* 20, 631–658.
2. Poretti, A., Boltshauser, E., and Doherty, D. (2014). Cerebellar hypoplasia: differential diagnosis and diagnostic approach. *Am. J. Med. Genet. C. Semin. Med. Genet.* 166C, 211–226.
3. Haldipur, P., and Millen, K.J. (2019). What cerebellar malformations tell us about cerebellar development. *Neurosci. Lett.* 688, 14–25.
4. Aldinger, K.A., Dempsey, J.C., Tully, H.M., Grout, M.E., Mehaffey, M.G., Dobyns, W.B., and Doherty, D. (2018). Rhombencephalosynapsis: Fused cerebellum, confused geneticists. *Am. J. Med. Genet. C. Semin. Med. Genet.* 178, 432–439.
5. Ucuncu, E., Rajamani, K., Wilson, M.S.C., Medina-Cano, D., Altin, N., David, P., Barcia, G., Lefort, N., Banal, C., Vasilache-Dangles, M.T., et al. (2020). MINPP1 prevents intracellular accumulation of the chelator inositol hexakisphosphate and is mutated in Pontocerebellar Hypoplasia. *Nat. Commun.* 11, 6087.
6. Rüschi, C.T., Bülsterli, B.K., Kottke, R., Steinfeld, R., and Boltshauser, E. (2020). Pontocerebellar Hypoplasia: a Pattern Recognition Approach. *Cerebellum* 19, 569–582.
7. van Dijk, T., Baas, F., Barth, P.G., and Poll-The, B.T. (2018). What's new in pontocerebellar hypoplasia? An update on genes and subtypes. *Orphanet J. Rare Dis.* 13, 92.
8. Akizu, N., Cantagrel, V., Schroth, J., Cai, N., Vaux, K., McCloskey, D., Naviaux, R.K., Van Vleet, J., Fenstermaker, A.G., Silhavy, J.L., et al. (2013). AMPD2 regulates GTP synthesis and is mutated in a potentially treatable neurodegenerative brainstem disorder. *Cell* 154, 505–517.
9. Mochida, G.H., Ganesh, V.S., de Michelena, M.I., Dias, H., Atabay, K.D., Kathrein, K.L., Huang, H.T., Hill, R.S., Felie, J.M., Rakiec, D., et al. (2012). CHMP1A encodes an essential regulator of BMI1-INK4A in cerebellar development. *Nat. Genet.* 44, 1260–1264.
10. Marin-Valencia, I., Gerondopoulos, A., Zaki, M.S., Ben-Omran, T., Almureikhi, M., Demir, E., Guemez-Gamboa, A., Gregor, A., Issa, M.Y., Appelhof, B., et al. (2017). Homozygous Mutations in TBC1D23 Lead to a Non-degenerative Form of Pontocerebellar Hypoplasia. *Am. J. Hum. Genet.* 101, 441–450.
11. Aldinger, K.A., and Doherty, D. (2016). The genetics of cerebellar malformations. *Semin. Fetal Neonatal Med.* 21, 321–332.
12. Sellick, G.S., Barker, K.T., Stolte-Dijkstra, I., Fleischmann, C., Coleman, R.J., Garrett, C., Gloyn, A.L., Edghill, E.L., Hattersley, A.T., Wellauer, P.K., et al. (2004). Mutations in PTF1A cause pancreatic and cerebellar agenesis. *Nat. Genet.* 36, 1301–1305.
13. Chang, J.C., Meredith, D.M., Mayer, P.R., Borromeo, M.D., Lai, H.C., Ou, Y.H., and Johnson, J.E. (2013). Prdm13 mediates the balance of inhibitory and excitatory neurons in somatosensory circuits. *Dev. Cell* 25, 182–195.
14. Hanotel, J., Bessodes, N., Thélie, A., Hedderich, M., Parain, K., Van Driessche, B., Brandão, Kde.O., Kricha, S., Jorgensen, M.C., Grapin-Botton, A., et al. (2014). The Prdm13 histone methyltransferase encoding gene is a Ptf1a-Rbpj downstream target that suppresses glutamatergic and promotes GABAergic neuronal fate in the dorsal neural tube. *Dev. Biol.* 386, 340–357.
15. Watanabe, S., Sanuki, R., Sugita, Y., Imai, W., Yamazaki, R., Kozuka, T., Ohsuga, M., and Furukawa, T. (2015). Prdm13 regulates subtype specification of retinal amacrine interneurons and modulates visual sensitivity. *J. Neurosci.* 35, 8004–8020.
16. Mona, B., Uruena, A., Kollipara, R.K., Ma, Z., Borromeo, M.D., Chang, J.C., and Johnson, J.E. (2017). Repression by PRDM13 is critical for generating precision in neuronal identity. *eLife* 6, e25787.
17. Whittaker, D.E., Oleari, R., Gregory, L.C., Le Quesne-Stabej, P., Williams, H.J., Torpiano, J.G., Formosa, N., Cachia, M.J., Field, D., Lettieri, A., et al. (2021). A recessive PRDM13 mutation results in congenital hypogonadotropic hypogonadism and cerebellar hypoplasia. *J. Clin. Invest.* 131, e141587.
18. Sobreira, N., Schiettecatte, F., Valle, D., and Hamosh, A. (2015). GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. *Hum. Mutat.* 36, 928–930.
19. Chemin, J., Siquier-Pernet, K., Nicouveau, M., Barcia, G., Ahmad, A., Medina-Cano, D., Hanein, S., Altin, N., Hubert, L., Bole-Feysot, C., et al. (2018). De novo mutation screening in childhood-onset cerebellar atrophy identifies gain-of-function mutations in the CACNA1G calcium channel gene. *Brain* 141, 1998–2013.
20. Le Fevre, A., Baptista, J., Ellard, S., Overton, T., Oliver, A., Gradhand, E., and Scurr, I. (2020). Compound heterozygous Pkd11l1 variants in a family with two fetuses affected by heterotaxy and complex Chd. *Eur. J. Med. Genet.* 63, 103657.
21. Al-Thihli, K., Afting, C., Al-Hashmi, N., Mohammed, M., Sliwinski, S., Al-Shibli, N., Al-Said, K., Al-Kasbi, G., Al-Kharusi, K., Merle, U., et al. (2021). Deficiency of acyl-CoA synthetase 5 is associated with a severe and treatable failure to thrive of neonatal onset. *Clin. Genet.* 99, 376–383.

22. Aldinger, K.A., Thomson, Z., Phelps, I.G., Haldipur, P., Deng, M., Timms, A.E., Hirano, M., Santpere, G., Roco, C., Rosenberg, A.B., et al. (2021). Spatial and cell type transcriptional landscape of human cerebellar development. *Nat. Neurosci.* *24*, 1163–1175.
23. Wizeman, J.W., Guo, Q., Wilion, E.M., and Li, J.Y. (2019). Specification of diverse cell types during early neurogenesis of the mouse cerebellum. *eLife* *8*, e42388.
24. Raj, B., Farrell, J.A., Liu, J., El Kholtei, J., Carte, A.N., Navajas Acedo, J., Du, L.Y., McKenna, A., Relic, D., Leslie, J.M., et al. (2020). Emergence of Neuronal Diversity during Vertebrate Brain Development. *Neuron* *108*, 1058–1074.e6.
25. Cao, J., O'Day, D.R., Pliner, H.A., Kingsley, P.D., Deng, M., Daza, R.M., Zager, M.A., Aldinger, K.A., Blecher-Gonen, R., Zhang, F., et al. (2020). A human cell atlas of fetal gene expression. *Science* *370*, eaba7721.
26. Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W.M., 3rd, Zheng, S., Butler, A., Lee, M.J., Wilk, A.J., Darby, C., Zager, M., et al. (2021). Integrated analysis of multimodal single-cell data. *Cell* *184*, 3573–3587.e29.
27. Butler, A., Hoffman, P., Smibert, P., Papalexis, E., and Satija, R. (2018). Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat. Biotechnol.* *36*, 411–420.
28. Kettleborough, R.N., Busch-Nentwich, E.M., Harvey, S.A., Dooley, C.M., de Bruijn, E., van Eeden, F., Sealy, I., White, R.J., Herd, C., Nijman, I.J., et al. (2013). A systematic genome-wide analysis of zebrafish protein-coding gene function. *Nature* *496*, 494–497.
29. Thisse, B., and Thisse, C. (2014). In situ hybridization on whole-mount zebrafish embryos and young larvae. *Methods Mol. Biol.* *1211*, 53–67.
30. Lee, M.S., Gippert, G.P., Soman, K.V., Case, D.A., and Wright, P.E. (1989). Three-dimensional solution structure of a single zinc finger DNA-binding domain. *Science* *245*, 635–637.
31. Barth, P.G. (1993). Pontocerebellar hypoplasias. An overview of a group of inherited neurodegenerative disorders with fetal onset. *Brain Dev.* *15*, 411–422.
32. Hoshino, M., Nakamura, S., Mori, K., Kawauchi, T., Terao, M., Nishimura, Y.V., Fukuda, A., Fuse, T., Matsuo, N., Sone, M., et al. (2005). Ptf1a, a bHLH transcriptional gene, defines GABAergic neuronal fates in cerebellum. *Neuron* *47*, 201–213.
33. Pascual, M., Abasolo, I., Mingorance-Le Meur, A., Martínez, A., Del Rio, J.A., Wright, C.V., Real, F.X., and Soriano, E. (2007). Cerebellar GABAergic progenitors adopt an external granule cell-like phenotype in the absence of Ptf1a transcription factor expression. *Proc. Natl. Acad. Sci. USA* *104*, 5193–5198.
34. Millen, K.J., Steshina, E.Y., Iskusnykh, I.Y., and Chizhikov, V.V. (2014). Transformation of the cerebellum into more ventral brainstem fates causes cerebellar agenesis in the absence of Ptf1a function. *Proc. Natl. Acad. Sci. USA* *111*, E1777–E1786.
35. Yamada, M., Terao, M., Terashima, T., Fujiyama, T., Kawaguchi, Y., Nabeshima, Y., and Hoshino, M. (2007). Origin of climbing fiber neurons and their developmental dependence on Ptf1a. *J. Neurosci.* *27*, 10924–10934.
36. Iskusnykh, I.Y., Steshina, E.Y., and Chizhikov, V.V. (2016). Loss of Ptf1a Leads to a Widespread Cell-Fate Misspecification in the Brainstem, Affecting the Development of Somatosensory and Viscerosensory Nuclei. *J. Neurosci.* *36*, 2691–2710.
37. Hibi, M., Matsuda, K., Takeuchi, M., Shimizu, T., and Murakami, Y. (2017). Evolutionary mechanisms that generate morphology and neural-circuit diversity of the cerebellum. *Dev. Growth Differ.* *59*, 228–243.
38. Itoh, T., Takeuchi, M., Sakagami, M., Asakawa, K., Sumiyama, K., Kawakami, K., Shimizu, T., and Hibi, M. (2020). Gsx2 is required for specification of neurons in the inferior olivary nuclei from Ptf1a-expressing neural progenitors in zebrafish. *Development* *147*, dev190603.
39. Hamling, K.R., Tobias, Z.J., and Weissman, T.A. (2015). Mapping the development of cerebellar Purkinje cells in zebrafish. *Dev. Neurobiol.* *75*, 1174–1188.
40. Ross, S.E., McCord, A.E., Jung, C., Atan, D., Mok, S.I., Hemberg, M., Kim, T.K., Salogiannis, J., Hu, L., Cohen, S., et al. (2012). Bhlhb5 and Prdm8 form a repressor complex involved in neuronal circuit assembly. *Neuron* *73*, 292–303.
41. Mzoughi, S., Di Tullio, F., Low, D.H.P., Motofeanu, C.M., Ong, S.L.M., Wollmann, H., Wun, C.M., Kruszka, P., Muenke, M., Hildebrandt, F., et al. (2020). PRDM15 loss of function links NOTCH and WNT/PCP signaling to patterning defects in holoprosencephaly. *Sci. Adv.* *6*, eaax9852.
42. Small, K.W., DeLuca, A.P., Whitmore, S.S., Rosenberg, T., Silva-Garcia, R., Udar, N., Puech, B., Garcia, C.A., Rice, T.A., Fishman, G.A., et al. (2016). North Carolina Macular Dystrophy Is Caused by Dysregulation of the Retinal Transcription Factor PRDM13. *Ophthalmology* *123*, 9–18.
43. Silva, R.S., Arno, G., Cipriani, V., Pontikos, N., Defoort-Dhellemmes, S., Kalhor, A., Carss, K.J., Raymond, F.L., Dhaenens, C.M., Jensen, H., et al. (2019). Unique noncoding variants upstream of PRDM13 are associated with a spectrum of developmental retinal dystrophies including progressive bifocal chorioretinal atrophy. *Hum. Mutat.* *40*, 578–587.
44. Manes, G., Joly, W., Guignard, T., Smirnov, V., Berthemy, S., Bocquet, B., Audo, I., Zeitz, C., Sahel, J., Cazevielle, C., et al. (2017). A novel duplication of PRDM13 causes North Carolina macular dystrophy: overexpression of PRDM13 orthologue in drosophila eye reproduces the human phenotype. *Hum. Mol. Genet.* *26*, 4367–4374.
45. Lal, D., Neubauer, B.A., Toliat, M.R., Altmüller, J., Thiele, H., Nürnberg, P., Kamrath, C., Schänzer, A., Sander, T., Hahn, A., and Nothnagel, M. (2016). Increased Probability of Co-Occurrence of Two Rare Diseases in Consanguineous Families and Resolution of a Complex Phenotype by Next Generation Sequencing. *PLoS ONE* *11*, e0146040.
46. Ming, X., Prasad, N., Thulasi, V., Elkins, K., and Shivamurthy, V.K.N. (2021). Possible contribution of cerebellar disinhibition in epilepsy. *Epilepsy Behav.* *118*, 107944.
47. Kani, S., Bae, Y.K., Shimizu, T., Tanabe, K., Satou, C., Parsons, M.J., Scott, E., Higashijima, S., and Hibi, M. (2010). Proneural gene-linked neurogenesis in zebrafish cerebellum. *Dev. Biol.* *343*, 1–17.
48. Fujitani, Y., Fujitani, S., Luo, H., Qiu, F., Burlison, J., Long, Q., Kawaguchi, Y., Edlund, H., MacDonald, R.J., Furukawa, T., et al. (2006). Ptf1a determines horizontal and amacrine cell fates during mouse retinal development. *Development* *133*, 4439–4450.
49. Glasgow, S.M., Henke, R.M., Macdonald, R.J., Wright, C.V., and Johnson, J.E. (2005). Ptf1a determines GABAergic over

- glutamatergic neuronal cell fate in the spinal cord dorsal horn. *Development* 132, 5461–5469.
50. Sotelo, C., and Dusart, I. (2009). Intrinsic versus extrinsic determinants during the development of Purkinje cell dendrites. *Neuroscience* 162, 589–600.
  51. Harper, R.M. (2000). Sudden infant death syndrome: a failure of compensatory cerebellar mechanisms? *Pediatr. Res.* 48, 140–142.
  52. Bright, F.M., Vink, R., Byard, R.W., Duncan, J.R., Krous, H.F., and Paterson, D.S. (2017). Abnormalities in substance P neurokinin-1 receptor binding in key brainstem nuclei in sudden infant death syndrome related to prematurity and sex. *PLoS ONE* 12, e0184958.
  53. Lavezzi, A.M., Corna, M., Matturri, L., and Santoro, F. (2009). Neuropathology of the Guillain-Mollaret Triangle (Dentato-Rubro-Olivary Network) in Sudden Unexplained Perinatal Death and SIDS. *Open Neurol. J.* 3, 48–53.
  54. Haldipur, P., Aldinger, K.A., Bernardo, S., Deng, M., Timms, A.E., Overman, L.M., Winter, C., Lisgo, S.N., Razavi, F., Silvestri, E., et al. (2019). Spatiotemporal expansion of primary progenitor zones in the developing human cerebellum. *Science* 366, 454–460.
  55. Guy, B., Zhang, J.S., Duncan, L.H., and Johnston, R.J., Jr. (2021). Human neural organoids: Models for developmental neurobiology and disease. *Dev. Biol.* 478, 102–121.

**Supplemental information**

**Recessive *PRDM13* mutations cause fatal perinatal brainstem dysfunction with cerebellar hypoplasia and disrupt Purkinje cell differentiation**

**Marion Coolen, Nami Altin, Karthyayani Rajamani, Eva Pereira, Karine Siquier-Pernet, Emilia Puig Lombardi, Nadjeda Moreno, Giulia Barcia, Marianne Yvert, Annie Laquerrière, Aurore Pouliet, Patrick Nitschké, Nathalie Boddaert, Antonio Rausell, Féréchté Razavi, Alexandra Afenjar, Thierry Billette de Villemeur, Almundher Al-Maawali, Khalid Al-Thihli, Julia Baptista, Ana Beleza-Meireles, Catherine Garel, Marine Legendre, Antoinette Gelot, Lydie Burglen, Sébastien Moutton, and Vincent Cantagrel**

## **Supplemental document S1: Detailed description of affected individuals and genetic findings**

### **Family 1**

Proband **F.1-1** was a female born from consanguineous parents of Tunisian origin. In the familial history, we can only note a complete removal of a basocellular carcinoma of the left eye in the mother. During the pregnancy, the second ultrasound screening identified bilateral foot malposition at 22 weeks of gestation (WG), confirmed by a specialized ultrasound examination at 26 WG; the latter exam also revealed mild cerebellar hemisphere hypoplasia and marked vermis hypoplasia. Fetal movements were found normal as well as amniotic fluid quantity. Fetal MRI at 30 WG identified wide pericerebellar spaces, vermis surface and cerebellar transverse diameter below the 3rd centile with abnormal shape of the fourth ventricle, not detectable primary and secondary fissures and smooth cerebellar hemisphere outline. Proband **F.1-1** was born at term (39 WG) by instrumental vaginal delivery, Apgar score was 1 and then 7, and birth weight was 3200g. She presented with marked hypotonia and major feeding difficulties with no sucking abilities, posterior cleft palate, microretrognathia, a supernumerary thumb flexion crease, an occipital angioma and normal patellar reflexes. Neurologic examination quickly evolved from a generalized hypotonia to a peripheral hypertonia and important reflex motor activity. At age 7 months, she already had numerous episodes of fainting without identified trigger probably due to either saliva inhalation or central origin. Oral feeding was not possible and nasogastric feeding was used in the first weeks of life. A scopolamine patch therapy was inefficient and led to position the baby lying on the belly to avoid complications. Head control was not acquired, she could somewhat smile and babble. Eye tracking was still intermittent. She had normal growth parameters (weight -0.8SD, median height, OFC -0.5SD). She had sleep disturbances with no more than 2-hour periods of sleep, and she required oxygen therapy. She presented round face, telecanthus, marked philtrum crease, retrognathia, marked palmar creases, tented vermilion of upper lip, mildly highly implanted columella, pes varus and genu varum. She was followed by a multidisciplinary team. At age 11 months visual interactions remained inconstant. At age 25 months, milestones have not improved significantly, she experienced additional and more severe faintness during a viral pneumopathy, oxygen needs increased and she passed away as the multidisciplinary concertation team did not opt for resuscitation. During her medical

course, she underwent an ophthalmological examination with a suspicion of papillary edema or hypoplasia and either normal or not interpretable evoked visual potentials and electroretinography. Evoked auditory potentials, cardiac, abdominal ultrasound, pelvis X rays and transfontanellar ultrasound were all normal. Brain MRI at the age of 2 months was not contributive due to the movement artefacts and was not performed thereafter due to major risk of anesthesia complications. A first electroencephalography showed numerous left hemisphere slow and wide paroxysms without status epilepticus which did not require therapy as the follow-up did not find any paroxysmal activity. Several tests were performed and obtained normal results including electromyography, electrocardiography including 24 hour-recording, thyroid function, sialotransferrin profiling and array-CGH. Sleep recording identified numerous episodes of desaturation and chronic hypercapnia.

During the fourth pregnancy (fetus **F.1-4**), similar manifestations as the first pregnancy were detected by close ultrasound follow-up, as well as a small posterior cleft palate in a female fetus (normal ultrasound at 17 WG and anomalies detected at 22 WG). The parents opted for a medical termination of the pregnancy at 24 WG. Fetal examination confirmed the posterior cleft palate and also identified a trabecular ventricular septal defect.

For the sixth pregnancy (sibling **F.1-6**), an ultrasound follow-up detected a transverse cerebellar diameter at 18th centile at 19 WG and below 5th centile at 21 WG; the second examination at 21 WG could also detect the vermis hypoplasia. At 24 WG, the same signs were found but also polyhydramnios (index = 25cm), probable right kidney duplication, but no cleft palate; it is noteworthy that examination conditions were incomplete. The parents chose to go on with the pregnancy. At 28 WG, the cerebellar biometric parameters decreased with transverse diameter below the 3rd centile, vermis hypoplasia and wide peri-cerebellar spaces as well as beginning of bilateral foot malposition but normal sucking movements and normal amniotic fluid quantity. At 33 WG, the ultrasound showed correct development of cerebellar hemispheres but marked vermis hypoplasia and normal supratentorial structures, fetal movements and amniotic fluid quantity were normal. The brain MRI at 33 WG also found the marked vermis hypoplasia with probable incomplete fissure development, wide pericerebellar spaces, brainstem hypoplasia with mildly pronounced inferior pontine sulcus, mild tapering of medulla oblongata and of cerebral peduncles; no other cerebral anomalies were detected. Similar findings were identified at the

last ultrasound examination at 37 WG. The patient had a similar clinical course in the neonatal period and the first weeks of life and passed away at age 4 months.

WES of F.1-1 and parents identified predicted deleterious variants in two genes not previously associated with Mendelian disorders. Compound variants found in *RGPD3*, NM\_001144013.1:c.364G>C (p.(Ala122Pro)) and NM\_001144013.1:c.2081A>T (p.(Asp694Val)) were excluded after segregation analysis. The remaining variant was in the *PRDM13* gene.

### **Family 2:**

The first pregnancy of this healthy consanguineous couple with no familial history of neurological disorders resulted in a late miscarriage at 21 GW for a triple pregnancy obtained by *in vitro* fertilization. During the second pregnancy (case **F.2-1**), ultrasound at 26 GW showed on the infra-tentorial space cerebellar hypoplasia with abnormal foliation and brainstem dysgenesis. The pregnancy was terminated at 31 GW. Pathological examination did not observe external or visceral malformation. Brain examination showed a normal size and development of the cerebrum with normal gyration development, marked hypoplasia of the cerebellum with poor lateral expansion. Neuropathological examination revealed a lack of development of the cerebellar cortex with low cellular density in the internal granular layer. Numerous Purkinje cells heterotopia in the white matter and the superior cerebellar peduncle were observed. The dentate nucleus was pachygyric and broken up and a residual rhombic lip with attached to the nodulus. The brainstem showed hypoplasia of the inferior olivary and pontine nuclei. Cranial nerves were correctly placed and pyramidal tracts were normal. Overall, the pathological exam diagnosed a form of pontocerebellar hypoplasia. Chromosome analysis by array, *TSEN54* gene sequencing as well as custom gene panel analysis for cerebellar congenital disorders were normal. During the third pregnancy (**F.2-2**) of this couple, the mother was referred due to recurrence of cerebellar hypoplasia detected by echography at 24 WG with unusual “foliation” vermis. The MRI at 29 WG confirmed hypoplasia of the hemisphere and pons and dysplasia of the vermis. The male infant was born at 34 GW, he weighed 2624 grams and measured 44 cm. The HC was 33.5 cm. His apgars were 4-7-8. He had hyperthelormism. He had no suction reflex, was hypotonic with poor motility, and abnormal movement of the limb. EEG was normal. Brain MRI reported reduced cerebellar and pons size. He had



a very mild respiratory distress syndrome related to prematurity. He received surfactant, was intubated for 48 h and then had pressor support and oxygenotherapy 25% for 48h. After day 4, the respiratory disease related to prematurity was over and the patient had spontaneous ventilation in ambient air. In the following days the frequency of apneas bradycardia increased and the child died at 22 days of life.

### **Family 3**

The proband **F.3-1** was born at 39+0 to a healthy Pakistani couple by normal vaginal delivery, following spontaneous onset of delivery. Her APGARs were 9-10-10. She presented with intrauterine growth retardation, with 2300g and OFC of 33.5cm. The parents were told antenatally that the baby was small for gestational age. On the second day of live, she presented with unexplained neonatal bradycardia and hypothermia, requiring admission in Neonatal Intensive Care Unit (NICU) for presumed sepsis, but with negative microbiology. During the one month that she was admitted in NICU, she had recurrent signs of respiratory distress, bradycardias and hypoglycaemia. She also had hypothyroidism and at least one clinical seizure. Her cranial ultrasound was normal. Metabolic and virological screening were normal. Brain MRI scan EEG, ECG and ECHO performed in the neonatal period were normal. At 9 months of age she presented to Emergency with altered consciousness and unwell since morning with vomiting and lethargy. She was unresponsive on arrival needing a bag valve mask and had bradycardia. She was hypertensive. EEG showed no focal epileptiform changes. Urgent brain MRI scan reported pontocerebellar hypoplasia (“Abnormal posterior fossa structures consistent with a form of pontocerebellar hypoplasia. The supratentorial brain appears normal.”). Full metabolic investigation was normal. Chromosome analysis by array-CGH was normal. On follow-up, diffuse cerebral dysfunction was observed in on EEG. Renal ultrasound scan identified grade 1 hydronephrosis bilaterally. Her albumin : creatinine ratios were just mildly elevated. She had mild proteinuria in one occasion. She was put on Amlodipine for her hypertension, achieving a good control. Further kidney ultrasounds including dopplers were reported as normal. Patient **F.3-1** had further admissions to Emergency presenting with unprovoked and unexplained episodes of encephalopathy, vomiting, floppiness and autonomic instability requiring pediatric intensive care unit admission (PICU). Subsequent clinic reviews and scans have noted that the pontocerebellar hypoplasia is

apparently non-progressive. She has hypotonia, mainly central, and a possible seizure disorder, with episodes of eye rolling and fast spikes in the posterior region, and she is on levetiracetam. She also presents with global developmental delay and diffuse cerebral dysfunction as demonstrated by EEG. She is making progresses, although slow and she does have increasing learning difficulties. She presents with high myopia and has jerky pursuit eye movements, with normal fundus. Patient F.3-1 had a Holter monitor at two years and ten months, which demonstrated sinus rhythm with very occasional marked sinus arrhythmia, frequent episodes of tachycardia in keeping with dysautonomia. Her blood pressure has normalised, her kidney function normalised and she does not require anti-hypertensive treatment anymore. Her intermittent high blood pressures and dysautonomia were considered to be due to her neurological issues. Her last measurements on 04/03/2021, aged 4 years and 6 months were: Weight: 12.2Kg - <0.4th centile; her height was 90.6cm - <0.4th centile; and her OFC was 46.4cm - below the 0.4<sup>th</sup>. The clinical genetics department was contacted again when the mother was pregnant with her second child; and we were asked to provide counselling. At this stage, we offered rapid whole exome sequencing using a trio analysis to **F.3-1**, and this has been reported as negative. **F.3-2** was born at 37+1 weeks via a normal delivery with approximately 2.37 kg, in good condition, and she was admitted to NICU as planned admission for observation. Unfortunately, she presented with neonatal autonomic problems, including temperature instability, bradycardic episodes and hypoglycemia. A recurrence was likely. The infection screening was negative. She had a suspected clinical seizure on day six and electric seizures on CFM at day seven onwards, and she has also been prescribed levetiracetam. Similarly to her elder sister, she presented with hypotonia, mainly central. However, she was less floppy than her sister. Rapid whole exome sequencing was done, and a genetic diagnosis was not identified. Her MRI scan showed that the cerebellar hemispheres are slightly small; but there was no other overt pontocerebellar hypoplasia. She now presents with developmental delay and slow weight gain. Her measurements on 24/02/2021, 7 months of age were: weight: 4.9kg - Centile: <0.4th (on - 4SD), length: 62cm - centile: 0.4<sup>th</sup>. Parents reported no further paroxysmal episodes after discharge from NICU, and refer to satisfactory developmental progresses. She's also doing generally better than her sister; and she has not yet had admissions to ED or PICU with crises like her sister had. She had a normal 24h Holter.

Whole-exome sequencing (WES) was performed by the Exeter Genomics Laboratory identified homozygous variants in three previously unknown disease genes: *C6orf163* (Chr6(GRCh37), g.88060133G>T, NM\_001010868.2: c.265G>T, p.(Ala89Ser)) ; *CAPZAI* (Chr1(GRCh37), g.113189893A>G, NM\_006135.2:c.101A>G, p.(Asn34Ser)) and *PRDM13* (Chr6(GRCh37), g.100062367A>T; NM\_021620.3:c.1856A>T, p.(His619Leu). All three variants were shared by the two affected girls. The variant in *CAPZAI* is known in dbSNP (rs202216073) and gnomAD with MAF<0.01% and its CADD score is 25. The variant in *C6orf163* has a CADD score of 26.6 and is absent from these databases. *PRDM13* variant is known to dbSNP (rs1173266789) and gnomAD (n=2) and its CADD score is 32. The three genes were added to GeneMatcher.

#### Family 4

The proband **F.4-3** was the third child of first cousin parents from Oman. He was born at term (40 wk+3) after a regular pregnancy, via C-section for breech presentation and abnormal CTG monitoring. At birth, Apgar score was 3 and 6 at 1 and 5 min, respectively. His birth weight and length were on the 10<sup>th</sup> percentile and his OFC was below 3<sup>rd</sup> percentile. He developed acute respiratory distress immediately after birth and evolved subsequently with recurrent apnea and hypoventilation episodes, likely of a central etiology; as he was ventilation dependent a decision was made to a tracheostomy. His severe post-natal failure to thrive was either related to the underlying etiology and/or to reduced caloric intake. He also had chronic constipation and recurrent vomiting. This patient presented with neonatal seizures and started an anti-epileptic treatment that was not associated with additional seizures. He had severe microcephaly with OFC below the 3<sup>rd</sup> percentile and dysmorphic features including low anterior hairline, with forehead localized hypertrichosis, thick eyebrows, narrow and short upslanting palpebral fissures, epicanthal folds, long fingers. Neurological examination showed axial hypotonia with distal hypertonia, spastic quadriparesis. The patient passed away the age of 16 months. Etiologic work-up were within normal limits, including karyotype, blood aminoacids, blood lactate, blood NH<sub>4</sub><sup>+</sup> and creatine kinase, urine organic acids, urine purines and pyrimidines, transferrin isoforms (CDG screening by HPLC), and acylcarnitine profile. Ophthalmological examination, ECG and heart ultrasound examination were normal. To further explore the genetic cause of the phenotype, Clinical Exome was

done at BGI Europe and reported as normal. Reanalysis of the raw data in-house (Sultan Qaboos University hospital), revealed *PRDM13* high impact mutations. Sanger sequencing was used to confirm the mutation in the affected patient. The DNA from parents and healthy siblings were not available.





Figure S1

### Figure S1 Expression of *PRDM13* during mammalian brain development

**A.** t-distributed stochastic neighbor embedding (t-SNE) projection plot of distinct cell populations obtained from 9,353 single cells from the mouse cerebellum at embryonic day 13.5 (E13.5). The single-cell RNA-seq dataset was retrieved from a publicly available repository stored in the GEO database under accession GSE120372<sup>18</sup> and re-analyzed using the Seurat package. Cells are color-coded by number of transcriptionally distinct clusters. **B.** *Prdm13* and *Ptf1a* expression levels displayed over the t-SNE projection plot (red, *Prdm13*-high cells; green, *Ptf1a*-high cells; yellow, overlap). **C.** Violin plot representation of *Prdm13* and *Ptf1a* relative expression levels across cell clusters. Cluster 10 is

characterized by high expression levels of both *Prdm13* and *Ptf1a*, which is a signature for cerebellum progenitor cells. **D-G**. Detection of *PRDM13* transcripts (red) by RNAscope in situ hybridization on sections through human embryos and fetuses. **D'**, **F'** and **G'** are higher magnifications of the region indicated by dotted lines in D, F and G respectively. **D**. Sagittal section through the brainstem at 10 PCW. *PRDM13* expression decreases and is maintained in scattered cells of the subventricular area (black arrows). **E**. Sagittal section through the cerebellum at 15PCW. *PRDM13* transcripts are no longer detected in the cerebellum at this stage. **F-G** Coronal section through a human embryo at CS21, showing the expression of *PRDM13* in the retina (**F**, **F'**) and hypothalamus (**G**, **G'**). Note the absence of *PRDM13* expression in cortical areas. Scale bars: 500  $\mu$ m.



**Figure S2 Expression of *prdm13* during zebrafish brain development**

**A.** Violin plot representation of *prdm13* expression levels across single-cell clusters from the 24hpf zebrafish heads<sup>19</sup>. Clusters are numbered as in the original publication. Clusters in which *prdm13* expression is enriched are highlighted by red stars. They correspond to clusters 2, annotated as “committed progenitors” (NPC); 7, annotated as “pharyngeal arch”; 12, annotated as “neurons” (Neu); 14, annotated as “rhombomere 7” (rh7) and 24, annotated as “rhombomere 2/3” (rh2/3). **B.** t-distributed stochastic neighbor embedding (t-SNE) projection plots of distinct cell populations obtained from

zebrafish heads at 24hpf<sup>19</sup>. In the left panel, cells are color-coded according to cluster annotations from the original publication. In the right panel, cells are colored in graded intensities, reflecting the expression levels of *prdm13*. Clusters in which *prdm13* expression is enriched are circled with dotted lines. **C-D**. Optical z-plane showing *prdm13* expression (ISH, magenta) at 36hpf (**C**) in the developing hypothalamus (white arrows) and retina (white arrowheads) and at 48hpf in the inner nuclear layer of the developing retina (**D**). Cell nuclei are counterstained with DAPI (blue). Scale bar: 50µm. **E**. Violin plot representation of *prdm13* expression levels across single-cell clusters from the 5dpf zebrafish brain<sup>19</sup>. Clusters are numbered as in the original publication. Clusters in which *prdm13* expression is enriched are highlighted by red stars. They correspond to clusters 1, 34 and 35, annotated as “ventral forebrain” and “hypothalamus” (Hyp); clusters 13, 25, 30 and 38, annotated as “progenitors” or “radial glia” (NPC); cluster 21, annotated as retina (amacrine, GABAergic interneurons) (AC) and cluster 45, annotated as “retina (muller glia)” (MG). **F**. Sagittal section through the zebrafish brain at juvenile stage (2-month-old, 2mpf), showing the expression of *prdm13* in blue. **F'** is a higher magnification of the region outlined by dotted squares in **F**. *prdm13* transcripts are detected in the cerebellar VZ (Cb VZ; black arrow in **F'**), which maintains a neurogenic activity at this stage in zebrafish. *prdm13* expression is also detected in the hypothalamus (Hyp) and dorsal ventricular zone of the medulla oblongata (MO). Tel: telencephalon; OT: Optic tectum. Scale bar: 200µm.



Table S1. Cerebellar measurements

	24 GW		31 GW		37 GW	
	Control	F.1-4	Control	F.2-1	Control	F.2-2
Cerebellum plus brainstem weight (SD)	5.2 g (± 0.7)	4.0 g (-1.7 SD)	12.2 g (± 2.2)	7 g (-2.4 SD)	21.4 g (± 3.4)	13 g (-2.5 SD)
Total brain weight (SD)	111.9 g (± 17.3)	97.0 g (-0.9 SD)	229.5 g (± 29.8)	204 g (-0.8 SD)	366 g (± 50.3)	349 g (-0.3 SD)
Cerebellum plus brainstem / Brain ratio (SD)	4.6 (± 0.29)	4.1 (-1.7 SD)	5.24 (± 0.35)	3.4 (-5.2 SD)	6.1 (± 0.66)	3.7 (-3.6 SD)

Cerebellar and total brain weights for the affected cases F.1-4, F.2-1 and F.2-2 and their stage-matched controls. Control measurements are from the study of AM Guihard-Costa and JC Larroche. Early Hum Dev. 1990 Jun;23(1):27-40.